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ABSTRACT  
   
Multicellular organisms use precise gene regulation, executed throughout 
development, to build and sustain various cell and tissue types. Post-transcriptional gene 
regulation is essential for metazoan development and acts on mRNA to determine its 
localization, stability, and translation. MicroRNAs (miRNAs) and RNA binding proteins 
(RBPs) are the principal effectors of post-transcriptional gene regulation and act by 
targeting the 3'untranslated regions (3'UTRs) of mRNA. MiRNAs are small non-coding 
RNAs that have the potential to regulate hundreds to thousands of genes and are 
dysregulated in many prevalent human diseases such as diabetes, Alzheimer's disease, 
Duchenne muscular dystrophy, and cancer. However, the precise contribution of 
miRNAs to the pathology of these diseases is not known.  
MiRNA-based gene regulation occurs in a tissue-specific manner and is 
implemented by an interplay of poorly understood and complex mechanisms, which 
control both the presence of the miRNAs and their targets. As a consequence, the precise 
contributions of miRNAs to gene regulation are not well known. The research presented 
in this thesis systematically explores the targets and effects of miRNA-based gene 
regulation in cell lines and tissues.  
I hypothesize that miRNAs have distinct tissue-specific roles that contribute to the 
gene expression differences seen across tissues. To address this hypothesis and expand 
our understanding of miRNA-based gene regulation, 1) I developed the human 
3'UTRome v1, a resource for studying post-transcriptional gene regulation. Using this 
resource, I explored the targets of two cancer-associated miRNAs miR-221 and let-7c. I 
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identified novel targets of both these miRNAs, which present potential mechanisms by 
which they contribute to cancer. 2) Identified in vivo, tissue-specific targets in the 
intestine and body muscle of the model organism Caenorhabditis elegans. The results 
from this study revealed that miRNAs regulate tissue homeostasis, and that alternative 
polyadenylation and miRNA expression patterns modulate miRNA targeting at the tissue-
specific level. 3) Explored the functional relevance of miRNA targeting to tissue-specific 
gene expression, where I found that miRNAs contribute to the biogenesis of mRNAs, 
through alternative splicing, by regulating tissue-specific expression of splicing factors. 
These results expand our understanding of the mechanisms that guide miRNA targeting 
and its effects on tissue-specific gene expression. 
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CHAPTER 1 
INTRODUCTION 
RNA - not just a messenger 
The genome of an organism contains all the information necessary to build, 
sustain, and replicate that organism. Understanding how this information produces 
complex life forms is a fundamental goal of genetics and genomics. The central dogma of 
molecular biology described by Francis Crick in 1956, explains the transfer of genetic 
information, from its storage as a nucleic acid code in DNA, through RNA which acts as 
a messenger, into proteins which carry out cellular functions [1]. The human body is 
estimated to consist of 37 trillion cells divided into various complex cell and tissue types 
[2], and based on the central dogma, it was expected that the human genome would 
contain 30k-100k protein-coding genes [3, 4]. Surprisingly, sequencing the human 
genome revealed that there are only 19-25k protein-coding genes [3-6] and that only 5% 
of the genome codes for proteins [7]. This number is surprisingly low given that the 
widely studied simple nematode Caenorhabditis elegans (C. elegans), with only 959 cells 
and 10 tissues, has 20k protein-coding genes [8]. Additionally, 40% of the protein-coding 
genes in both organisms perform similar functions [7]. These findings suggest that 
focusing on the proteome alone may be insufficient to understand the differences in 
complexity between organisms.  
RNA, initially described in the central dogma as an intermediary messenger 
molecule for genetic information, is involved in a variety of cellular functions including 
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enzymatic catalysis, and gene regulation (Figure 1.1). The ability of RNA to perform all 
these functions provides evidence for the RNA world hypothesis, the idea that at one 
point in evolution RNA existed as the sole molecule required for life [9]. This hypothesis 
suggests that a central role for RNA in cell biology pre-dates much of the organismal 
complexity seen today (Figure 1.1). As such, it is not surprising that RNA-based 
mechanisms contribute to tissue differentiation and have expanded throughout evolution  
[10-12]. In metazoans, RNA contributes to gene regulation at the epigenetic [13], 
transcriptional [14], post-transcriptional [15] and translational stages [16], and is essential 
for development (Figure 1.1). 
Post-transcriptional regulation is a hypernym used to indicate a series of 
mechanisms that act on RNA and produces a disparity between the transcriptomes and 
proteomes of organisms [17-20]. While post-transcriptional regulation acts on almost all 
 
 
Figure 1.1 - RNA has a central role in cell biology. RNA is a highly active molecule, 
that can store genetic information similar to DNA, and also perform enzymatic catalysis 
similar to proteins. RNA contributes to gene regulation throughout expression, from 
epigenetic control of DNA states to the translation of proteins. 
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RNA, it is perhaps best characterized for its effects on mRNA, where it can impact 
cellular localization [21], translation and degradation [22] (Figure 1.1). Many prevalent 
human diseases such as cancer, Alzheimer’s disease, Duchene muscular dystrophy, and 
diabetes have disruptions in post-transcriptional gene regulation. However, the causality 
of these observations and the precise roles of post-transcriptional regulation in these 
conditions is not fully understood. Understanding the regulation of RNA in cells can 
reveal mechanisms that produce and maintain tissues and potentially reveal avenues of 
therapeutic intervention for human diseases. The research presented in this thesis 
explores some of these RNA-based regulatory networks, with a particular focus on post-
transcriptional regulation and how it contributes to tissue-specific gene expression. 
 
3’untranslated regions mediate post-transcriptional regulation. 
 
The 3’untranslated regions (3’UTRs) of genes, unfortunately, named for what 
they do not do, are sequences that are found between the STOP codons and poly-A tails 
of transcripts and interact with many RNA binding proteins (RBPs) and non-coding 
RNAs to regulate mRNA post-transcriptionally [23] (Figure 1.2).  
While 3’UTRs are generally less conserved than coding sequences [24], they 
contain conserved regions that are recognized by regulatory elements and determine 
localization [21], translation [25] or degradation [26, 27] of the transcript  (Figure 1.2). 
The first reports of conserved elements in 3’UTRs arose from homology studies using 
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actin genes. Isoforms of actin expressed in similar tissues, across related vertebrate 
species, shared conserved 3’UTRs, while actin isoforms expressed in different tissues did 
not, implying a tissue-specific role for 3’UTRs [28, 29]. 3’UTRs are essential for 
embryonic development where they contribute to the maternal to zygotic transition in 
many model organisms [30-33], and then continue to produce tissue-specific gene 
regulation throughout development [34-36]. In C. elegans the 3’UTR can determine gene 
expression even over the promoters of genes, exemplifying the role of 3’UTRs even 
beyond embryogenesis [37].  
The 3’ends of 3’UTRs are formed by the recognition of the polyadenylation 
sequence (PAS), a hexameric sequence that is canonically AAUAAA, by the cleavage 
and polyadenylation complex, which directs cleavage of the transcript ~21nt downstream 
of the PAS (Figure 1.2). The importance of the PAS was first identified in thalassemia 
[38], a condition characterized by decreased hemoglobin production, where a single point 
 
 
Figure 1.2 – The 3’ untranslated regions (3’UTRs) of genes contain many 
regulatory elements that can direct mRNA fate. The 3’UTR of a transcript is the 
region between the STOP codon and poly-A tail and has binding sites of RNA binding 
proteins, miRNA and other regulatory factors. 
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mutation in the PAS of the 2-globin drastically reduced the mRNA levels of this gene in 
erythrocytes [38].  
To study the role of 3'UTRs in diseases and throughout development, many 
studies have sequenced and annotated the 3’UTRs of various model organisms and found 
that a majority of 3’UTRs in metazoans are polyadenylated at multiple sites [39-42]. The 
mechanism by which the cleavage and polyadenylation machinery distinguishes between 
different PAS elements, to produce a single coding sequence with different 3’UTR 
isoforms, is known as alternative polyadenylation (APA) (Figure 1.3). Due to APA, a 
single coding sequence is expressed with different 3’UTR isoforms, which alters the 
post-transcriptional regulation of the gene (Figure 1.3). Accordingly, changes in 3'UTR 
length due to APA occur during cell differentiation [36, 40, 43-46], proliferation [47], 
and diseased states such as cardiomyopathy [48-50] and cancer [51].  
 
Figure 1.3 - APA can determine the availability of binding sites for regulatory 
elements. Alternative polyadenylation (APA) is a mechanism by which the cleavage 
and polyadenylation machinery distinguishes between PAS sites to produce a single 
coding sequence with different 3’UTR isoforms. The PAS site used determines the 
3’UTR and regulatory sequences effecting the upstream coding sequence.  
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The mechanisms behind cleavage and polyadenylation have been studied in 
depth, and the core protein complex, capable of cleavage and polyadenylation in vitro, 
consists of approximately 20 proteins [52, 53]. In addition to the PAS, the cleavage and 
polyadenylation complex recognizes sequences both up and downstream of it, and the 
presence of these other sequences are believed to strengthen the usage of particular PAS 
elements [54]. The in vivo, active polyadenylation complex is estimated to contain 
upwards of 80 proteins [52] and, outside of the core complex, the roles of many of these 
proteins in cleavage and polyadenylation remains unknown. The polyadenylation 
complex is well conserved across eukaryotes [55] and the size of the complex, when 
compared to its relatively simple task in mRNA processing is perhaps an indication of the 
importance of regulating sites of polyadenylation in organisms.  
A recent study of nine tissue-specific transcriptomes in C. elegans revealed that 
most genes commonly expressed between tissues have different 3'UTR isoforms due to 
APA, and changes in 3'UTR length allow transcripts to be differentially expressed in a 
tissue-specific manner [56, 57]. There is evolutionary conservation of the tissue-specific 
APA patterns in genes with more than one UTR isoform, implying that APA may be 
functional [18]. These studies provide evidence that at least in specific instances, 3’UTRs 
are modulated by APA, and interact with small non-coding RNAs and RNA binding 
proteins (RBPs) in ways that are important for gene regulation. 
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Discovery of miRNAs - essential regulators of metazoan development 
 
MicroRNAs(miRNAs) are small non-coding RNAs that are ~22nt in length and 
play an indispensable role in the development of multicellular organisms [15]. 
Contributions of the miRNA pathway to development were apparent from its initial, 
discovery in C. elegans where the efforts of Victor Ambrose and Gary Ruvkun in 1993, 
showed that the interactions between the non-coding gene lin-4 and the protein-coding 
gene lin-14 were essential for the developmental progression of the worm through its 
larval stages [58, 59] (Figure 1.4). They found that lin-4 has significant sequence 
complementarity to the 3’UTR of lin-14 which led to an interaction that decreased the 
translation of lin-14 [58, 59]. The decrease of lin-14 protein levels caused by lin-4 directs 
the developmental transition from the L1 to the L2 larval stage [58, 59] (Figure 1.4).  
A second discovery in the miRNA pathway was made in 1998 by Bohmert et al., 
who found that a mutation in a specific family of proteins resulted in developmental 
defects to tissue differentiation in the plant Arabidopsis thaliana. They named this family 
of proteins Argonaute due to similarities in the phenotypes of the mutants to the octopus 
Argonauta Argo (Figure 1.5). Further studies of the Argonaute proteins found that they 
are the effectors in small RNA pathways, and deficiencies in the miRNA pathway likely 
caused the mutant phenotypes with defects to tissue differentiation. The mammalian 
Argonaute protein AGO-2 is predominantly responsible for the miRNA pathway, and 
studies in mice have shown that mutations leading to disruptions in this protein are 
embryonic lethal, demonstrating its importance in early development. 
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Figure 1.4 – The initial discovery of miRNAs revealed that they play a role in 
regulating developmental timing in C. elegans. Left panel – Wild type N2 worms 
compared to heterochronic mutants showing the lin-4 and lin-14 phenotypes. The lin-4 
worms develop slowly and do not produce all of the adult tissues while the lin-14 
mutants develop too rapidly and mature before reaching their full size. The graph below 
illustrates the changes, across developmental stages, in the levels of the miRNAs lin-4 
and let-7, and the corresponding changes in the protein levels of their targets LIN-14 and 
LIN-41. Right panel – The let-7 miRNA is conserved in C. elegans, D. melanogaster and 
humans. The binding site for the miRNA let-7 in the protein-coding gene lin-41 gene is 
conserved between C. elegans, Drosophila, and zebrafish.  Figures adapted from: Left 
panel – Wormbook, C. elegans microRNAs. Vella, M. C, and Slack, F. J. 2005 [60]. 
Right panel – Pasquinelli, A.E. et al. 2000 [61]. 
 
 
Figure 1.5 – Mutations in the proteins that carry out the miRNA pathway were 
discovered to display developmental defects in Arabidopsis thaliana. When 
compared to the wild type the Argonaute mutants were unable to differentiate its 
tissues to develop stems and leaves. Due to similarities of the phenotype to Argonauta 
Argo, the protein family was named Argonaute. Figure adapted from Bohmert et al. 
1998 [62]. 
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MiRNAs were believed to be an oddity of gene regulation in the worm until 
another study performed at the Ruvkun lab revealed that a different miRNA, let-7 and its 
target in the 3’UTR of lin-41 is conserved across species (Figure 1.4). Following this 
discovery, the field of miRNA research gathered interest and over 2000 miRNAs have 
been annotated in the human genome [63], and miRNAs have become well established in 
post-transcriptional gene regulation. 
 
MicroRNA biogenesis and mechanisms of action 
A significant effort has been made to study the biogenesis of miRNAs and how 
they carry out their cellular functions in metazoans (Figure 1.6) [15, 64, 65]. These 
studies have revealed that miRNAs are transcribed from the genome by RNA polymerase 
II to produce a primary transcript known as the pri-miRNA [66], which contains a 
complementary stretch of nucleotides that fold it into a hairpin structure comprising a 
double-stranded region at the miRNA sequence (Figure 1.6). The hairpin structure is 
recognized by enzymes which cleave the pri-miRNA and release the pre-miRNA. Pre-
miRNAs are transported out of the nucleus by the nuclear membrane RNA transporter 
exoprotein-5, and once in the nucleus, the double-stranded region of the pre-miRNA is 
recognized by the enzyme Dicer which cleaves the hairpin sequence to produce a double-
stranded RNA that is ~21nt in length (Figure 1.6). The double-stranded RNA, composed 
of the miRNA and miRNA* is then loaded into an Argonaute family protein. The 
Argonaute protein is the catalytic component of a large protein complex known as the 
RNA induced silencing complex (RISC), which executes the miRNA pathway (Figure 
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1.6). The RISC discriminates between the two miRNA strands based on thermodynamic 
properties of the strands [67], then degrades one of them and uses the other as a guide to 
identify target sequences in the 3’UTRs of mRNAs.  
 
 
Figure 1.6 - The biogenesis and functions of miRNAs in metazoans. MiRNAs are 
transcribed from the genome by RNA polymerase II to produce pri-miRNAs. Due to 
sequence complementarity within the transcript, they fold to form a characteristic 
hairpin structure that is recognized by DGCR8 and Drosha which cleaves just below the 
stems of the hairpins to produce the pre-miRNAs. Once the pre-miRNAs are transported 
out of the nucleus, the enzyme Dicer recognizes their structure due to its double-
stranded nature and cleaves the hairpin to release a ~22nt miRNA:miRNA* duplex 
which then binds to the RNA induced silencing complex (RISC). The RISC degrades 
one of the miRNA strands and uses the other as a guide to identify miRNA targets. 
Targets of miRNAs are held in translational repression or cleaved and degraded. Figure 
adapted from Barca-Mayo and Lu, 2012 [69] 
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  The RISC is guided to target sites by the miRNA based on sequence 
complementarity and Watson and Crick base-pairing (Figure 1.7). Initial efforts looking 
at requirements for miRNA targeting indicated that sequence complementarity at a region 
of the miRNA, nucleotides 2-7, referred to as the "seed" region was essential for target 
recognition. The discovery of the crystal structure of an Argonaute protein complex with 
a miRNA clarified the importance of the seed for miRNA target recognition. The 
predominant Argonaute protein involved with the miRNA pathway in humans, AGO-2 
was crystallized bound to a guide miRNA [68] (Figure 1.8) and revealed that the seed 
region of the miRNA extends into a cleft of the protein which allows probe and form base 
pairs with the 3'UTRs of mRNAs (Figure 1.8). The initial base pairing of the seed region 
of the miRNA with the target 3’UTR is believed to facilitate further interactions between 
the 3’UTR and the 3’end of the miRNA (Figure 1.8). 
 
 
 
Figure 1.7 – A model representing a miRNA interacting with its target 3’UTR. 
Base pairing between the miRNA and the 3'UTR facilitates target identification. Strict 
complementarity at the "seed" region, nucleotides 2-7 at the 5' end of the miRNA, is the 
best indicator of miRNA targeting. Mismatches are tolerated downstream of the seed 
and compensatory base pairing at the 3'end can strengthen site recognition. 
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The result of a miRNA targeting a 3'UTR is decreased protein expression. 
However, the mechanism that produces this effect can vary between organisms [70-72]. 
In plants, targeting by miRNAs requires perfect base pairing and leads to the degradation 
of the target [70]. While in metazoans miRNA targeting can result in the mRNA being 
held in translational repression or to degradation [71].  
 
 
Figure 1.8 – The crystal structure of human AGO-2 in complex with a guide 
RNA. The Argonaute protein AGO-2 is shown in blue; and the miRNA is shown in 
red and yellow. The crystallography data potentially reveal the structural basis for 
miRNA target recognition. The white arrow indicates a cleft in the protein structure to 
which the bases of the seed region (red) of the guide miRNA extend. This allows the 
seed region to form initial base pairing with target 3’UTRs and is important for target 
recognition. Crystallography data was adapted from Schirle, N.T. et al. 2012 [68] 
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There are two proposed mechanisms of action by which miRNAs carry out their 
functions. Experiments done with cell lines show that miRNAs interfere with the 
formation of the translation initiation complex at the 5'cap [73]. This mechanism is 
further evidenced by in vitro studies that show miRNA-based repression does not act on 
IRES-dependent translation [74]. Evidence that the RISC associates with the CCR4-NOT 
deadenylation complex [89] suggest that miRNA targeting leads to deadenylation of the 
poly-A tail of mRNAs[75]. The effects of miRNA based deadenylation of targets have 
been seen in zebrafish [76], and C. elegans [77] and ultimately leads to the degradation of 
the target mRNA. MiRNA targeting can also lead to re-localization of mRNA to P-
bodies, though if this is for degradation of the mRNA, or for it to be held translationally 
repressed to then later be released is unknown [78]. Perhaps these mechanisms are 
staggered, and that miRNA targets are held translationally silenced before degradation, 
though this implies that miRNA targeting is an irreversible process [79].  
In animals, knocking out the miRNA pathway leads to lethality during embryonic 
development [80-82] with defects in cell differentiation [80, 83, 84], indicating an 
essential role for the miRNA pathway in producing tissues. Efforts to profile the miRNAs 
expressed in a tissue-specific manner have revealed that miRNAs can be tissue-restricted, 
even in fully developed tissues [85, 86], indicating that perhaps miRNAs may have 
tissue-specific roles beyond embryogenesis. Despite the withstanding questions about the 
precise mechanisms by which miRNAs act, their impact on gene regulation and its 
consequences for development is established and highlights the need to identify miRNA 
targets.  
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Methods for identifying microRNA targets 
 
Due to the seed region being just six nucleotides, miRNAs are believed to be able 
to target many hundreds to even thousands of genes [87]. The most widely used method 
for identifying miRNA targets is through bioinformatic means using predictive 
software[88]. Initial predictive software identified miRNA target sites by locating regions 
of seed complementarity in genomes and requiring these sites to be evolutionarily 
conserved [87, 89, 90]. While complementarity of the seed element remains the best 
identifier for miRNA binding sites, many recent studies have revealed that miRNA 
targeting can occur even in the presence of mismatches in the seed, suggesting that the 
seed region is not a sufficient predictor of miRNA targets [11, 91-94]. An analysis 
performed by Wolter et al. 2014 [94] on three widely used miRNA target prediction 
software, TargetScan [95], PicTar [96], and DIANA-microT [97], revealed that each of 
the software failed to identify ~30% of the experimentally validated miRNA targets. The 
most likely cause for this discrepancy is the application of conservation filters that 
prevent the identification of species-specific interactions.  
More recent predicative software allow for mismatches at the seed and utilize 
thermodynamic properties [99] or a combinatorial approach [100] to identify miRNA 
binding sites and ignore conservation requirements. The consequence of removing the 
conservation filter is that these algorithms predict far more targets for each miRNA (over 
7000 for some let-7 family members [101]), although the false positive rates are yet to be 
established for these predictions. While bioinformatic predictions can be a useful starting 
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point for studying miRNAs, in its current state identifying functional miRNA targets 
requires validation by wet bench approaches. 
Wet bench efforts to identify miRNA targets can be divided into, biochemical 
approaches, high-throughput sequencing-based approaches, and functional reporter 
assays [102]. Biochemical methods such as PCRs, Western and Northern blotting have 
been used since the very discovery of miRNAs to test miRNA-gene interactions and its 
consequences. While these methods are exceptionally well established, and accurate, they 
are not easily applied to test miRNA targeting in high-throughput. 
Many of the high-throughput approaches utilize next-generation sequencing along 
with cross-linking and immunoprecipitation (CLIP) based methods to identify miRNA 
targets from cell lines, tissue samples and in the case of C. elegans the entire organism 
[103-106]. While these techniques can detect a large number of miRNA targets at the 
genomic scale, there are two stipulations to these techniques, 1) it is difficult to 
distinguish transient and non-functional interactions from functional and biologically 
relevant interactions 2) it does not identify the miRNA responsible for targeting and is 
reliant on predictive software to do so.  
Another sequencing-based approach is to overexpress particular miRNAs in cell 
lines using DNA constructs and perform transcriptome or proteome sequencing. This 
approach avoids the pitfall of identifying functional targets, however, is limited in 1) the 
capacity to study in vivo biology as it overexpresses a miRNA which changes the system 
being investigated 2) its inability to distinguish indirect interactions, where 
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downregulation of particular genes by a miRNA can then have secondary downstream 
effects on the transcriptome or proteome.    
Reporter-based approaches overcome some of the limitations of sequencing and 
biochemical techniques as they can measure in vivo, functional interactions. Reporter 
systems make use of easily quantifiable proteins by attaching them upstream of query 
3’UTRs then measuring changes to protein production in the presence of a test miRNA. 
One of the most widely used reporter systems to identify miRNA targets are luciferase 
assays [107], which utilize the ability of the luciferase enzymes to produce accurately 
quantifiable levels of luminescence in the presence of their respective substrates. 
Generally, the luciferase assays have been used to screen a small number of individual 
miRNA-target interactions, but recently Wolter et al. 2014, adapted it to the high-
throughput 96-well  format [108]. One of the caveats to applying this approach at a 
genomic scale is that it needs a large number of easily manipulated, cloned 3'UTRs. 
Most studies that identify miRNA targets use a combination of the approaches 
described above, where bioinformatic predictions and high-throughput sequencing efforts 
producing genomic miRNA-target databases, validated with reporter-based experiments 
and biochemical means. 
 
Dysregulation of microRNAs in cancer 
 
Given the expansive roles of miRNAs in regulating gene expression, it is perhaps 
unsurprising that dysregulation of miRNAs is seen in all the phenotypes associated with 
cancer[109] (Figure 1.9).  
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The first reported deregulation of miRNAs in cancer was in chronic lymphocytic 
leukemia, which indicated that the miRNAs miR-15 and miR-16 are in a region of 
chromosome 13 deleted in more than half of B-cell chronic lymphocytic leukemia cases 
[110]. These two miRNAs target oncogenes such as BCL2 [111], CCND1 and WNT3a 
[112] and the deletion of both miRNAs allow these oncogenes to be overexpressed [113]. 
A second tumor suppressing miRNA let-7 was found to be broadly involved with 
many cancers and is deleted in lung, breast, urothelial, ovarian, and cervical cancers 
 
Figure 1.9 – MiRNAs are implicated in all the hallmarks of cancer. Based on the 
targets of a miRNA, it can act as either an oncogene (green) or a tumor suppressor (red). 
The precise contributions of most of these miRNAs to the phenotypes are unknown 
Figure adapted from Hanahan, D. & Weinberg, R.A. 2011 [114] 
 
  18 
[115]. Some of the oncogenes identified as a target of let-7 are in the RAS family of 
proteins. This discovery, made using C. elegans, showed that let-7 targets the RAS 
homolog let-60 [116]. Human have three RAS proteins, H-ras, K-ras, and N-ras, all of 
which contain binding sites for let-7 in their 3’UTRs [116]; mutations in these binding 
sites are associated with increased lung and breast cancer [117, 118]. Bioinformatic 
software predicts that let-7 can target over 1000 genes, and many of these predictions 
have not yet been validated [90]. A recent high-throughput study using a dual-luciferase 
reporter-based approach found that let-7 targets several genes involved with cell cycle 
progression, DNA synthesis, and mitosis [11].  
The previously described miRNAs act in a tumor-suppressing capacity, however, 
miRNAs can also act as oncogenes and are referred to as oncomiRs[109, 119]. For 
example, the miRNA miR-10b is a well-characterized oncomiR found overexpressed in 
over 18 cancer types and is correlated with increased invasion and metastasis, evading 
apoptosis, and proliferation [120]. Importantly upregulation of miR-10b is associated with 
poor prognosis and clinical progression of cancer [121]. miR-10b can target the retinoic 
acid pathway at multiple points and is a potential mechanism by which miR-10b regulates 
cell differentiation [94].  
A less well-characterized miRNA, miR-221 is experimentally validated to target 
tumor-suppressing genes such as ARHI, CDKN1C, Kip-1 (p-27), PTEN, and PUMA, but 
also the oncogenes c-Kit, MMP1, and SOD1 [122]. The overall role of miR-221 seem to 
be oncogenic as the over-expression of this miRNA can be seen in nine different types of 
cancers, and its expression level is correlated with poor patient prognosis. Further 
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identifying targets for this miRNA can help with understanding the mechanisms leading 
to poor prognosis, and perhaps reveal avenues of therapeutic intervention [123].  
Many studies have profiled miRNAs across cancer types and found them to be 
widely dysregulated [124, 125], however, the mechanisms which lead to this 
dysregulation of miRNAs are not clear. Several profiling studies have suggested the 
possibility of using miRNAs as biomarkers for detecting the onset, progression and 
treatment response of cancer [126-128]. In the case of chronic myelogenous leukemia, 
the expression of miRNAs miR-10a, miR-17-92, miR-29a, miR-150 and miR-203 have all 
been shown to change across disease progression [129]. Whether changes to miRNAs can 
act as drivers of cancer or are passenger changes induced by more dominant mutations is 
of great interest but has not yet been determined [130].  
Initial studies targeting miRNAs as therapeutics in cancer and other diseases have 
been promising, with significant results in treating cancer in mice and hepatitis C virus in 
humans [131, 132]. However, a recent clinical trial targeting the miR-34 family in 
primary liver cancer was terminated due to patients demonstrating immune-related 
adverse effects (ClinicalTrials.gov Identifier: NCT01829971) with the precise cause for 
these effects being currently unreported. There are still many outstanding questions about 
the basic biology of miRNAs, including the mechanisms by which miRNAs identify 
targets, the extent of miRNA-based regulation, biological consequences of targeting, and 
their tissue-specific roles, all of which present significant limitations for using miRNAs 
as therapeutics. 
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Hypothesis and specific aims 
 
Given the well-established spatial and temporal regulation of miRNA expression 
and their potential to regulate gene pathways, it is conceivable that miRNAs play an 
essential role in producing and maintaining tissues. However, other than individual 
miRNA-gene interactions, the precise tissue-specific functions of miRNAs are not well 
understood. There is a need to identify the targets of miRNAs in high-throughput, 
especially in the context of diseases, where dysregulation of miRNAs is well 
characterized, but their contributions to diseased states are not well known. 
I hypothesize that miRNAs have distinct tissue-specific roles that contribute to the 
gene expression differences seen across tissues. To address this hypothesis, I developed 
and used resources to study post-transcriptional regulation in high-throughput, optimized 
a system to identify miRNA targets in specific tissues of a living organism, and tested 
some of the consequences of tissue-specific miRNA targeting for gene expression. The 
approaches and techniques used to achieve each of these conditions are discussed below. 
 
Aim #1: Develop the human 3’UTRome v 1 (h3’UTRome): A resources to rapidly 
identify miRNA targets in high-throughput (Chapter 2) 
  The first aim addresses the lack of high-throughput resources to study post-
transcriptional gene regulation in humans. I have developed the h3'UTRome, a collection 
of cloned and sequenced human 3'UTRs, in a modular system that is convenient for 
downstream analysis. To better understand the principles that guide miRNA targeting, I 
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screened candidate 3'UTRs from the h3'UTRome for targeting by two miRNAs 
implicated in cancer. The results from this study revealed potential mechanisms by which 
miRNAs influence tissue identity and are perhaps dysregulated in cancer.   
 
Aim #2: Identify tissue-specific targets of miRNA in the intestine and body muscle 
tissues of Caenorhabditis elegans. (Chapter 3) 
Tissue-specific targets of miRNAs are not well characterized, and this aim seeks 
to address this deficiency by profiling the miRNA targets in the tissues in the model 
organism C. elegans. I optimized, validated and used this system to isolate, sequence and 
annotate the miRNA targets from the intestine and body muscle of mixed stage C. 
elegans. The identified miRNA targets showed that intestine and body muscle use this 
form of regulation to different extents and that miRNA targets in each tissue correlate 
with tissue-specific functions. 
 
Aim #3: Explore the consequences of miRNA-based gene regulation to tissue-specific 
gene expression patterns in C. elegans. (Chapter 4) 
Many of the tissue-specific targets of miRNAs in the intestine and body muscle 
are RBPs. However, the functional relevance of miRNAs targeting these genes is not 
known. In this aim, I utilized biochemical, genetic and genomic approaches to identify 
the consequences of miRNAs targeting of specific RBPs and found evidence that 
suggests an unexpected role for miRNAs in regulating the biogenesis of mRNAs. 
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CHAPTER 2 
The h3’UTRome v 1 – A publicly available compendium 
of human 3’UTRs 
 
Publication note 
The research reported in this chapter was previously published in BMC genomics. 
Kasuen Kotagama, Cody S. Babb, Justin M. Wolter, Ronan P. Murphy and Marco 
Mangone. A human 3’UTR clone collection to study post-transcriptional gene regulation. 
BMC Genomics 2015 16:1036. All co-authors have granted permission for this work to 
be included in this dissertation.  
 
Overview 
 
3'untranslated regions (3'UTRs) are the sequences located immediately 
downstream of the STOP codon of mature mRNAs. Although historical attention focused 
on protein coding sequences and upstream regions, 3'UTRs have recently become subject 
to intense study because they are targets of a variety of regulatory molecules, including 
RNA binding proteins (RBPs) and small non-coding RNAs (ncRNAs), that recognize 
small cis-elements present in the 3'UTRs. These cis-elements play critical roles in 
deciding the fate of the mRNA via various mechanisms. These include co-transcriptional 
processing, modulating protein translation, mRNA localization and trafficking, and 
mRNA degradation and stability [148]. Disruption of these processes is known to affect 
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diverse developmental and metabolic processes and contributes to the various diseases, 
including neurodegenerative diseases, diabetes, and cancer [130, 149-151]. 
 RBPs play a role in every aspect of mRNA biogenesis, such as stability, localization, 
translation, and decay. The human transcriptome contains approximately ~400 proteins 
with distinct RNA binding domains [152], and their deregulation is linked to major 
neurodegenerative disorders, cancer, and muscular dystrophies. Compared to 
transcription factors, which generally bind highly specific linear DNA sequence 
elements, elements in 3'UTRs targeted by RBPs are generally more degenerate. Since 
RNA is a single-stranded molecule and RBP binding is mostly dictated by local folding 
and polarity, this can be challenging to identify bioinformatically [152]. Consequently, 
RBPs have the potential to bind to multiple elements in different 3'UTRs, leading to 
intricate, dynamic, and mostly unknown networks of RNA-protein interactions. 
3'UTRs are also targeted by a class of post-transcriptional regulators known as 
microRNAs (miRNAs), which are short non-coding RNAs that bind to complementary 
sequences in the 3'UTRs of metazoans [148]. Once bound, based on the degree of 
complementarity, miRNAs can induce either translational repression or mRNA 
degradation [153]. MiRNAs canonically recognize targets in 3'UTRs via Watson-Crick 
base pairing, requiring complementarity with as few as six consecutive nucleotides 
between the 5'end of a mature miRNAs and the 3'UTR of a target transcript [153]. 
However, recent evidence suggests that miRNAs do not require perfect complementarity 
with target 3'UTRs to induce functional translational repression, and non-canonical 
interactions are frequent [109]. Because miRNA target elements are degenerate and 
  24 
small, they are difficult to detect. Thus, a vast majority of biologically relevant miRNA 
targets are still unknown. Based on bioinformatic predictions of miRNA-binding sites in 
3'UTRs, it has been proposed that each miRNA controls large networks of hundreds of 
mRNAs [154]. However, a recent analysis of the predictive performance of several of the 
most prominent prediction algorithms, such as TargetScan [110], PicTar [111] and 
DIANA-microT [112] report extremely high false negative rates [53, 109, 155]. While 
these algorithms are very useful for candidate gene approaches to identify miRNA 
targets, the extremely high error rates make high-throughput target detection challenging.  
When this challenge is paired with the absence of a publicly available and comprehensive 
3'UTR library, the field currently lacks tools to systematically study miRNA targets, 
which is the gold standard in miRNA biology. 
Several genomic resources are currently available to systematically study gene 
expression and its regulation in humans. The human ORFeome, for example, is a 
collection of over 12,000 human protein-coding genes cloned in modular vectors and 
optimized to study the dynamics of gene expression [156, 157]. The ORFeome has been 
used to characterize genome-wide protein-protein interaction networks, leading to 
important discoveries relevant to human disease [156]. High-throughput resources such 
as this can significantly advance our understanding of gene functions in multicellular 
organisms. Unfortunately, such a standardized HT tool to detect and study regulatory 
elements in 3'UTRs are not available since 3'UTR sequences are not present in the 
ORFeome. Some individual 3'UTR clones are available commercially, but these products 
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have sporadic coverage, are too expensive for HT studies, use only proprietary vectors 
and are not compatible with the ORFeome. 
Furthermore, endogenous full-length 3'UTRs frequently undergo alternative 
processing in a tissue-specific fashion [158], which limits the biological relevance of 
experiments that use truncated or partial 3'UTRs. A recent study attempted to overcome 
the limited availability of 3'UTRs by using ~240,000 short RNA sequences, containing 
all possible 9-base nucleotide permutations immobilized on microarrays to study the 
binding requirements of 205 human RBPs [152]. Although this work and others highlight 
important binding properties of RBPs, they do not necessarily reflect natural settings, 
where accessory elements near binding sites that may cooperate with the RBPs targeting 
are not present. 
Recently, our group experimented with the usage of a pilot human full-length 
3'UTR library to detect miRNA targets in 3'UTRs using a scalable dual-luciferase assay 
named Luminescent Identification of Functional Elements in 3'UTRs (3'LIFE) [109, 
159]. Although we cloned and screened only ~300 query 3'UTRs, the proof of principle 
3'LIFE screen was highly effective at the rapid and efficient discovery of many novel 
targets for two cancer relevant miRNAs, let-7c and miR-10b [109]. This pilot screen 
demonstrates the value of such an unbiased HT approach and supports the need for the 
development of a publicly available genome-wide 3'UTR library. 
Furthermore, there is a critical need in the field for a high-quality and 
standardized human 3'UTR resource, which could be widely used in the community to 
study miRNAs and RBPs using full-length 3'UTRs in unbiased and HT experiments. 
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To overcome these limitations, we have developed the first publicly available and high-
quality human 3'UTR clone library, sequenced verified and cloned in modular vectors 
amenable to various downstream analyses. This resource enables the systematic study of 
3'UTR biology, can be used to efficiently detect miRNA and RBP targets at high 
resolution, and study mRNA localization and dynamics. In the context of disease states, 
this library allows the study of crucial disease alterations in post-transcriptional 
processing, such as disease-specific: 1) mRNA mislocalization, 2) alternative 
polyadenylation, 3) altered miRNA expression, 4) mutation of RNA binding protein 
elements in 3'UTRs, and 5) more generally, the contribution of post-transcriptional gene 
regulation to gene output in disease initiation and progression. 
 
Results 
 
The human 3’UTRome v1 clone collection (h3’UTRome v1) consists of 1,461 
unique, cloned and sequence-validated human 3’UTRs from transcription factors, kinases 
and other regulatory genes (Figure 2.1). This collection is contained in modular 
# of 3’UTRs targeted 1,815 
# of 3’UTRs cloned 1,461 
% cloning success 80.1% 
 
Figure 2.1 - Overview of 3’UTRs targeted for the h3’UTRome v1. We targeted a 
panel of 1,815 unique human 3’UTRs and successfully cloned, and sequence 
verified 1,461 unique 3’UTRs (80.1 % cloning success). 
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Gateway® compatible Entry vectors is amenable for large screens and is publicly 
available to the community through the at the DNASU plasmid repository 
(http://dnasu.asu.edu). (https://dnasu.org/DNASU/Home.do). 
 
Primer design and genomic PCR 
As a first release, we targeted and designed genomic primer pairs encompassing 
the 3’UTR regions of 1,815 human protein-coding genes using the human genome 
release 19 (GRCh37/hg19 Feb. 2009)[133]. The forward primers used for the genomic 
PCR were designed to anneal within the last exon of the target gene, ending with the 
gene-specific STOP codon in frame with the rest of the transcript (Figure. 2.2).  
This expedient allowed us to increase the melting temperature of each forward 
primer since the G/C content drops considerably after the STOP codon. In addition, 
designing the forward primer within the open reading frame provides the 3’UTR with its 
original gene-specific STOP codon at its 5’end, allows for convenient in-frame 
 
 
Figure 2.2 - Primer design used to target 3’UTRs and downstream processing 
elements. The forward primers used to amplify 3’UTR genomic loci were 
anchored within the last exon of each transcript, ending with the gene-specific 
STOP codons. The reverse primers bound 150 nucleotides downstream of the 
annotated transcript. 
 
forward
primer
STOP
reverse
primer
150nt
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integration with the human ORFeome library, which instead lacks termination codons 
[134] (Figure. 2.2). The melting temperatures of the primers ranged from 50 to 76 °C. 
Given this wide range of temperature, we opted for a touchdown genomic PCR approach, 
starting at 66 °C and decreasing by 1 °C each cycle [94]. The reverse primers were 
designed to target a genomic site 150 nt downstream of the annotated transcript, 
encompassing downstream elements that may play a role in mRNA 3’end formation 
(Figure. 2.2). We added the Gateway® recombination elements attB2 (forward primers) 
and attB3 (reverse primers) to the 5’ends of the genomic primers, to facilitate the cloning 
into Gateway® compatible Entry vectors. A minimum of 200 ng of genomic DNA per 
reaction was required to obtain an enriched PCR product while minimizing non-specific 
amplicons, which is known to impact the recombinational cloning procedure. The 
complete pipeline used in this study is shown in (Figure 2.3) 
 
 
 
 
 
Figure 2.3 - Flow chart summarizing the cloning pipeline of the h3’UTRome v1. 
Genomic PCR was performed using 3’UTR specific primers and the PCR products were 
shuttled into Gateway® Entry vectors by recombinational cloning. Single cloned 
colonies were isolated and screened based on the expected 3’UTR length using PCR 
and gel electrophoresis. Bacterial colonies passing the screen were then re-arrayed, and 
the cloned 3’UTRs were sequenced using the Sanger sequencing method. The sequence-
verified 3’UTRs were submitted to the DNASU plasmid repository for public 
distribution. 3’UTRs that were not successfully cloned were subject to the second pass 
of cloning. 
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Gateway® recombinational cloning 
The full understanding of gene expression must consider both transcriptional and 
post-transcriptional regulation, requiring attention to the transcriptional promoter, the 
ORF and the regulatory sites within the 3’UTR. The human 3’UTRs in this collection 
were cloned into the pDONR P2r-P3 Gateway® Entry vector (Invitrogen) using BP 
recombinant cloning. This vector is part of the three-fragment Gateway® technology, 
which allows modular cloning of a given promoter, an ORFeome entry and, 
correspondent 3’UTR to be assembled in order into a single vector in the same reaction. 
This will enable investigators to combine these 3’UTRs with different ORFs (which are 
already available in the ORFeome collection) to create both natural and novel regulatory 
contexts. Current protein expression vectors typically rely on viral 3’UTRs, such as the 
SV40 polyA, which often do not reflect natural translational levels or post-transcriptional 
regulation. In addition, natural 3’UTRs may contribute to proper localization and 
stability. This technology is also compatible with the 3’LIFE assay system and has been 
previously used to screen for functional miRNA targeting in 3’UTRs [94]. Successfully 
cloned colonies were isolated and grown in LB and analyzed by colony PCR using 
primers specific to the pDONR P2r-P3 backbone. The PCR amplicons were analyzed by 
agarose gel electrophoresis and screened based on the expected lengths of the 3’UTRs 
(Figure 2.4). We observed an inverse correlation between the size of the inserted 3’UTR 
and the BP cloning success rate (Figure 2.5). A size bias during the BP cloning reaction 
has been previously reported [135], with a decreased efficiency for amplicons greater 
than 1,000nt and in agreement with our observations [135]. 
  30 
3’UTRs in the h3’UTRome v1 are enriched with longer 3’UTR isoforms and on 
average contain longer 3’UTRs than those within the human transcriptome (Figure 2.6). 
The nucleotide lengths of the human 3’UTR clones in this release span from 200nt to 
2,500nt and have a median length of 1,159nt, as opposed to the median length of 3’UTRs 
within the human genome, which is 1,040nt (Figure 2.6, purple and red arrows). 
 
Figure 2.4 - Electrophoretic analysis of PCR products from the complete 
h3’UTRome v1. The sizes of 3’UTRs from 1,461 PCR reactions were analyzed on 
ethidium bromide stained gels.  
 
 
Figure 2.5 - Percentage of cloning success vs. 3’UTR length. The efficiency of 
3’UTR cloning (blue line) decreases ~30 % beyond the length of 1,000 nucleotides in 
the cloned dataset (red). The maximum cloning efficiency for amplicons smaller than 
499 nt was 92.8%, while the cloning efficiency of 3’UTRs greater than 2,000nts was 
64.3% 
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The first pass of cloning produced a yield of 1,410 bacterial colonies with PCR 
products of the expected size. We performed a second pass on all 405 missed 3’UTRs 
and gained an additional 172 3’UTRs, a 12% increase to the total number of size-verified 
clones (Figure 2.3). 
 
Sanger sequencing 
A total of 1,582 clones verified by size were subsequently sequenced using the 
Sanger method using a custom primer anchored within the P2rP3 plasmid backbone. We 
used Perl scripts to perform BLAT alignments [133] using the Sanger trace files obtained 
 
Figure 2.6 - Length of the 3’UTRs of genes in the human genome hg19 vs. the 
h3’UTRome v1. The 3’UTRs in the h3’UTRome v1 range between 200 nt to 2,500 nt, 
and are enriched for longer 3’UTR isoforms. The median length of 3’UTRs in the 
h3’UTRome v1 is 1,159 nt (purple arrow) while in the human genome hg19 it is 1,040 
nt (red arrow). 
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during the sequencing. Our analysis revealed that out of the initially targeted 1,815 
unique 3’UTRs, 1,461 were successfully sequence verified (~80% success rate from 
genomic PCR to sequence verification). 
 
3’UTRome library overview 
The human 3’UTR clones contained in the h3’UTRome v1 are unbiased towards 
any particular regions of the genome and correspond to ~6-10% of the total protein-
coding genes present in each chromosome (Figure 2.7). The source of DNA used for the 
genomic PCR was GM12878, a lymphoblastoid cell line of female origin recommended 
as a Tier 1 cell line by the ENCODE project. Over 54% of the 3’UTRs in the 
h3’UTRome v1 overlap with genes present in the hORFeome V8.1 (Figure 2.8) [136].  
We targeted 971 3’UTRs of genes already present in the ORFeome and 
successfully cloned 790 3’UTRs (Figure 2.8). For this first release, we targeted 
predominantly 3’UTRs of genes previously classified as transcription factors [137, 138], 
kinases [139], and RBPs [140]  (Figure. 2.9). We targeted the 3’UTRs of this class of 
genes because they have widespread regulatory functions and have corresponding 
ORFeome clones. The h3’UTRome v1 release includes 3’UTRs for 985 transcription 
factors, 171 Kinases and 156 RBPs (Figure. 2.9). 
 
Library distribution 
The h3’UTRome v1 library is distributed by the DNA repository DNASU 
(http://dnasu.asu.edu), a public plasmid repository hosted at the Biodesign Institute at 
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Arizona State University, which already distributes over 180,000 individual plasmids and 
full genome collections, including the human ORFeome [141]. Users can either search 
for a given 3’UTR clone, a plate or order the complete dataset. Many researchers are not 
interested in HT screens nor have the resources for large screens in their departments, but 
want to detect miRNA targets, mutations, or truncation of regulatory elements in the 
3’UTR of their gene of interest. These researchers will be able to accelerate their research 
significantly because they can now order the correct ORF, 3’UTR clones and the vectors 
they need for their analysis at a reduced cost. To simplify the ordering procedure, we 
have given a unique ID prefix ‘HSU’ to the human 3’UTRs available with this release.  
 
 
 
 
 
 
 
 
 
chr. ORFs # cloned % 
1 1,987 182 9.2 
2 1,214 117 9.6 
3 1,052 82 7.8 
4 747 54 7.2 
5 860 79 9.2 
6 1,025 104 10 
7 876 88 10 
8 660 58 8.8 
9 759 74 9.7 
10 732 68 9.3 
11 1,270 75 5.9 
12 1,010 102 10 
13 314 32 10.2 
14 596 62 10.4 
15 560 47 8.4 
16 807 80 9.9 
17 1,142 102 8.9 
18 266 28 10.5 
19 1,378 227 16.5 
20 525 63 12 
21 215 16 7.4 
22 427 33 7.7 
X 813 70 8.6 
Y 59 - - 
 
Figure 2.7 - The h3’UTRome v1 contains 3’UTRs for 6-10% of the 
ORFs within each chromosome. None of the 3’UTRs cloned in this 
release originates from the Y chromosome, as the source of genomic 
DNA used was of female origin. 
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Figure 2.8 - The degree of overlap between the h3’UTRome v1 and the hORFeome 
V8.1. More than half of the 3’UTRs cloned in the h3’UTRome v1 contain 
corresponding clones present in the hORFeome V8.1. 
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Figure 2.9 - The h3’UTRome v1 is enriched for the 3’UTRs of genes involved 
with gene regulation. Predominantly it contains 3’UTRs of transcription factors 
(33.9%), kinases (40.8%), and RNA binding proteins (32.4%). 
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3’LIFE validation screen 
The 3’LIFE screen is a high throughput dual luciferase assay, previously shown to 
detect functional repression of test 3’UTRs by query miRNAs [94, 108]. The 3’LIFE 
screen utilizes Gateway® cloning technology and is fully compatible with the 
h3’UTRome v1. To demonstrate the usability and functionality of this library we have 
selected 87 human 3’UTRs from the h3’UTRome v1 library (Appendix A) and screened 
for miRNA targets of two disease-relevant miRNAs: let-7c and miR-221 using the 
3’LIFE assay [94, 108]. let-7c is a well-characterized tumor suppressor gene, is down-
regulated in many cancers, and is known to target genes in the RAS pathway [116]. 
Conversely, miR-221 is frequently overexpressed in breast cancer, hepatocellular 
carcinomas, glioblastoma and prostate cancer [142-145], and has been shown to target 
several tumor suppressor genes such as Kip-1(p-27), CDKN1B, CDKN1C, PTEN, ARHI 
and PUMA [143, 146, 147]. In addition, miR-221 is known to be involved with muscle 
damage repair and atherosclerosis [134, 148]. One of the goals of this experiment was to 
use this 3’UTR library to rapidly identify bona fide miRNA targets from false targets 
predicted by miRNA targeting software. These programs, such as TargetScan [95], 
PicTar [96] and DIANA-microT [97] are known to have high false negative rates (~43%) 
[22, 94, 149] and false positive rates (~66%) [94, 150, 151], and cannot be used alone to 
definitively assign targets. 
These 87 human-3’UTRs were enriched with let-7c and miR-221 predicted and 
validated targets from all three prediction software algorithms (Appendix A) (9 predicted 
and 3 validated targets for let-7c, and 10 predicted and 9 validated targets for miR-221). 
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For the let-7c screens, we also included two genes that contain validated miRNA targets 
identified in a previous screen (Appendix A)[94]. In addition, since miRNAs 
preferentially target genes within the same regulatory pathways [94], and let-7c was 
previously shown to target the RAS family of genes [94, 116], we were interested to test 
if let-7c could also target an additional 25 members of this pathway, as defined by Gene 
Ontology [152] and KEGG databases (Appendix A)[153]. 
We shuttled 87 human 3’UTRs from the h3’UTRome v1 clone library into the 
3’LIFE vector using LR recombination reactions. Using this custom library, we 
performed 435 fully automated transfections and dual luciferase experiments. The results 
of the screen are shown in (Figure 2.10). Using a cut-off for functionally repressed targets 
at a repression index of 0.8 and a p-value <0.05, we obtained 19 statistically significant 
hits for let-7c, and 13 for miR-221 (Figure 2.10). 
Our results validate 4 out of 9 of the let-7c targets predicted by prediction 
software algorithms [95-97]. Within the predicted hits, we detected all three previously 
validated targets (CDC25A, TRIM71, and BCL2L1) and an unvalidated, predicted target 
(RNF7) (Figure 2.10). Furthermore, we detected an additional 10 novel and unpredicted 
targets for let-7c (Figure 2.10). We found that one of these novel targets PAK3 was 
predicted by the prediction algorithm miRanda [99], which takes into account non-
canonical seed interactions. Of note, 3 targets within this group (MCM2, BUB1B, and 
GMNN) were previously correlated indirectly with let-7 expression [154]. 
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Figure 2.10 (next page) - The h3’UTRome v1 as a resource to detect miRNA 
targets in high throughput. 3’LIFE screen performed on 87 human 3’UTRs 
extracted from the h3’UTRome v1, queried against two miRNAs let-7c and miR-221. 
The repression index was calculated for each 3’UTR and indicates a normalized ratio 
between Firefly and Renilla luciferases. A minimum cutoff for repression was drawn 
at 0.8, and the asterisks denote statistically significant repression (p < 0.05). The top 
hits for each miRNA are displayed as a heat map on the right panels. Increased 
intensity of color indicates greater repression. 18 top hits were identified for let-7c of 
which 3 were previously validated (as denoted by the arrows). 13 top hits were 
identified for miR-221 of which 4 were previously validated (as denoted by the 
arrows) 
 
  38 
For miR-221, our results validated 4 out of 10 of the miR-221 targets predicted by 
the prediction software [95-97], and an additional 4 out of 9 of the targets previously 
validated by others (WEE1, ETS2, FMR1, and KIT) [155-158]. Interestingly, we were 
unable to detect repression in 3’UTRs of 5 genes previously known to contain miR-221 
responsive elements (CDKN1C, FOS, IRF2, ICAM1, PAK1) [159-163]. Upon further 
review, we found that repression of all five targeted elements was demonstrated using 
truncated sections of the 3’UTR. Thus, the observation that the 3’LIFE screen did not 
detect these targets could be caused by the inability of these elements to recruit miR-221 
when expressed within their full-length endogenous 3’UTRs, or by the presence of 
alternative polyadenylation events that cause the loss of these elements [94]. Two targets 
of miR-221 called by the prediction software [95-97] were also not detected as hits in our 
assay (KHDRBS2 and RORB). We also discovered 9 novel and unpredicted targets for 
miR-221 not anticipated by major prediction software [95-97] or detected by others. 
Within this group, FRAP1 was the only gene predicted by miRanda [99]. Perfect 
complementarity within the seed region is considered the canonical indicator of miRNAs 
targeting. Interestingly, most of these novel targets do not always contain canonical 
seeds. Recent studies indicate that miRNAs are also capable of recognizing non-
canonical elements in target mRNAs [94, 150, 164, 165], supporting our findings. 
9 out of 18 bioinformatically predicted targets are validated by our experiments 
[95-97] (50% false positive rate), which is in accordance with the false positive rates of 
prediction algorithms reported in previous studies [22, 94, 149-151]. In previous studies, 
we used repression data from the 3’LIFE assay to identify and validate functional 
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miRNA binding sites [94]. With experimentally validated miRNA target sites, targeting 
signatures can be extrapolated to refine target predictions for specific miRNAs. 
Interestingly, while the 3’LIFE assay is designed to detect repression of 3’UTRs 
by miRNAs, we identified several 3’UTRs that significantly enhanced the expression of 
the luciferase reporter gene in the presence of let-7c and miR-221 (Figure 2.10). Perhaps 
these enhancements are caused by increase stability of a given 3’UTR due to direct or 
indirect interactions with the query miRNAs.  
The ability to systematically screen large numbers of human 3’UTRs allowed in-
depth analysis of high-confidence target genes regulated by different miRNAs and may 
reveal novel mechanisms that miRNAs use to regulate biological processes. For example, 
a gene ontology analysis of the let-7c top hits showed an enrichment for genes involved 
in cell cycle checkpoint regulation, while a similar analysis for miR-221 revealed a 
relationship with genes involved in negative regulation of muscle differentiation. 
In addition, out of the 25 genes involved in the RAS pathway, our screen 
identified 7 genes directly targeted by let-7c (RhoB, PAK1, PAK3, BRAF, NFKBIA, 
BCL2L1, KIT), suggesting a role for let-7c in regulating this pathway. 
 
Discussion 
 
The h3’UTRome is a publicly available tool for studying miRNA-based gene regulation 
3’UTRs contain powerful regulatory elements that are critical in various 
biological processes, yet remain poorly characterized due to the absence of genomic tools 
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that allow their systematic study. In this work, we have prepared the first human 3’UTR 
clone collection named h3’UTRome v1, which is produced to a single high-quality 
standard. This library is compatible with the cloning technology used to produce the 
human ORFeome, expanding the potential of well-established operating methods for high 
throughput experimentation. The h3’UTRome v1 library is sequence verified, and readily 
available to the community with simple online access to information through the DNASU 
repository [166], at a low cost to all scientists with minimal restriction. The h3’UTRome 
v1 can be easily used in HT experiments to systematically study RBP targeting in 
3’UTRs, mRNA localization and the role of small ncRNAs in post-transcriptional gene 
regulation. 
In order to demonstrate its utility, we performed a screen with 87 human 3’UTRs 
cherry-picked from the h3’UTRome v1 and rapidly identified 27 miRNA targets for two 
disease-relevant miRNAs, let-7c and miR-221. Within this pool, we identified 18 novel 
targets for these two miRNAs, which were previously uncharacterized (67%). In addition, 
we were able to eliminate 9 out of 18 bioinformatically predicted targets (50% false 
positive), and rapidly associate miRNA activities to biological pathways using a rapid 
screening technology. We found that while let-7c targets predominantly oncogenes, miR-
221 targets a mix of both tumor suppressors and oncogenes, implying that miR-221 may 
be involved with more context-dependent regulation of gene expression [122] (Figure 
2.11).  
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Experimental 
 
Primer design 
DNA primer sequences were designed using custom Perl scripts using the 
annotated 3’UTR sequences in the Human Genome release 19 (GRCh37/hg19 Feb. 2009) 
[133]. The forward primers were anchored upstream of the last exon of each gene and 
included the gene specific endogenous STOP codons in frame with the ORFome library 
(Figure 2.2). The reverse primers were designed to target sites 150nt downstream of the 
longest annotated transcript, as per the RefSeq annotation, in order to include 
downstream 3’end processing elements (Figure 2.2). Forward and reverse primers were 
fused to the attB2 (5’-GGGGACAGCTTTCTTGTACAAAGTGGAG-3’) and attB3 (5’-
 
Figure 2.11 – Genes identified as targets of miR-221 and let-7c using 3’UTRs 
from the h3’UTRome. miR-221 targets a mix of oncogenes and tumor suppressors 
indicating that the role of this miRNA in cancer may be dependent on the cancer 
type and context. Conversely, almost all the targets of let-7c are oncogenes, further 
endorsing the tumor suppressing role of this miRNA. We found that let-7c targets 
the RAS pathway is targeted at multiple points, from receptor tyrosine kinases, 
downstream signaling kinases and final effectors of the pathway 
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GGGGACAACTTTGTATAATAAAGTTG-3’) Gateway® sequences to allow modular 
cloning into pDONR P2rP3 Entry vectors. The full list of primers used is available 
through DNASU (https://dnasu.org/DNASU) [166]. The first release of the h3’UTRome 
V1 targeted a panel of 1,815 3’UTRs and is enriched for transcription factors, kinases, 
RNA binding protein and other regulatory genes (Figure 2.9). The length of the 3’UTRs 
cloned in this release ranges between 200 and 2,500nt in length, which is larger than the 
average size of human 3’UTRs (Figure 2.6). 
 
Genomic DNA 
We used the NA12878 DNA sample obtained from the NIGMS Human Genetic 
Cell Repository at the Coriell Institute for Medical Research (Camden, New Jersey). This 
genomic DNA was extracted from the GM12878, a B-lymphocyte cell line of a human 
female subject. Once received, the genomic DNA was diluted to a concentration of 
200ng/µl, aliquoted in 96-well PCR reactions, and stored at -80oC until use. 
 
Genomic touchdown PCR 
The reactions were conducted using Platinum Taq polymerase (Invitrogen) in 96-
well plates using 200ng of genomic DNA per reaction. The reaction conditions were 
maintained as per the manufacturers protocol with changes to the annealing temperature 
of the reaction. The PCR conditions included 16 cycles of touchdown PCR, where the 
temperature of the annealing phase decreased by 1°C per cycle, ending at a temperature 
of 50°C. The reaction proceeded for 15 more cycles at an annealing temperature of 55°C. 
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The resulting PCR products were visualized on by electrophoresis on 96-well agarose 
gels and screened by size to determine successful amplicons. 
 
Gateway® BP recombination reaction and transformation 
Site-specific DNA recombination was used to clone the human 3’UTR PCR 
amplicons into the Gateway® Entry vector pDONR P2r-P3 (Invitrogen), using BP 
Clonase II Enzyme Mix kit (Invitrogen, Carlsbad, CA) following the manufacturer’s 
specifications. DH5α E. coli cells were transformed with 1µl of the resultant reaction 
mixture, and screened the following day for successful recombinants using Lysogeny 
Broth (LB) agar plates with Kanamycin (Kan) antibiotic. 
 
3’UTR isolation and size screening 
In order to isolate single clonal populations, unique bacterial colonies for each 
3’UTR clone were picked from the LB plates, and grown overnight in 96 deep-well 
plates containing LB (500mL) with Kanamycin resistance (50μg/mL) (total colonies 
picked=1,824). The resultant bacterial growths were used as a template to perform colony 
PCR reactions using M13 DNA primer pairs. The amplicons were then analyzed in 96-
well agarose gels and positive clones were initially screened based on their expected size 
(Fig. 1d). Up to three more colonies for genes that did not satisfy our quality control 
inspection were picked (total colonies picked=753), and rescreened by repeating the 
bacterial colony PCR step. Bacterial colonies that passed the initial screen were re-
arrayed and stored in glycerol stocks, while the primer pairs of the remaining genes were 
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used in a second pass, starting at genomic PCR to capture any 3’UTR missed (Figure 
2.3). 
 
Sanger sequencing 
PCR analysis with M13 DNA primer pairs was performed for each positive 
3’UTR clone, using overnight bacterial growths as a template and Phusion® Taq 
polymerase (New England Biolabs), as per manufacturers protocol. These PCR 
amplicons were then sent for sequencing at the DNA Lab, School of Life Sciences, 
Arizona State University, using the sequencing primer 1FP2rP3 seq (5’-
GCATATGTTGTGTTTTACAGTATTATGTAG-3’) which binds ~100nt upstream of 
the recombination element in the P2rP3 plasmid. 1,461 3’UTR clones successfully 
sequence verified and passed this step. The trace files for each 3’UTR clone successfully 
screened are available through DNAsu website [166]. Using custom a BioPerl script with 
Blat integration [133] we mapped our sequencing results to 1,461 unique 3’UTRs in the 
human genome. 
 
3’LIFE screen 
The 3`LIFE assay was performed as previously described [108]. We re-arrayed 
bacterial colonies from a panel of human 3’UTRs from the h3’UTRome v1, and grew the 
plate over-night in a 96 deep-well format using 200mL of LB in presence of kanamycin 
(50μg/mL). We used 1μl of the resultant overnight culture to perform the colony PCR 
with Phusion Taq polymerase (Invitrogen) as per manufacturers protocol. The amplicons 
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from the PCR reaction were shuttled into the pLIFE-3’UTR vector (DNASU Plasmid ID: 
EvNO00601503) by LR recombination using LR Clonase enzyme (Invitrogen) as per 
manufacturers protocol. 1μl of the resultant LR reaction mixture was transformed in 
DH5 E. coli cells. The transformed cells were then plated on LB agar plates containing 
ampicillin (100μg/ml), and incubated overnight at 37oC. Single bacterial colonies were 
isolated and grown overnight in 500mL of LB containing ampicillin (100μg/mL). The 
resultant overnight bacterial growth was screened based on size using agarose gel 
electrophoresis. Bacterial colonies from wells passing the screen were frozen as glycerol 
stocks and also grown overnight for 96-well plasmid DNA extraction as previously 
described [94, 108]. In order to express let-7c miRNA we used the pLIFE-miR let-7c 
construct [94, 108].  
The miRNA miR-221 was extracted from human genomic DNA derived from 
GM12878 cells using DNA primers containing Gateway® recombination elements 
(forward primer – 5`-
GGGGACAGCTTTCTTGTACAAAGTGGAGTTTCAACATGATGTCATGATTAAAT
G-3`; reverse primer- 5`-
GGGGACAACTTTGTATAATAAAGTTGCACCTTATCTCTGGTTTACTAGGCTG-
3`). The amplified PCR amplicon was cloned into pLIFE-miR (DNASU Plasmid ID: 
EvNO00601504) vector using LR Clonase II enzyme as per manufactures protocol 
(Invitrogen). We designed the positive and negative controls for miR-221 targeting by 
introducing 22nt long complementary sequences for the 3p arm (positive control) and 5p 
arm (negative control) arms of miR-221 into the SV40 3’UTR by site directed 
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mutagenesis (Quikchange®, Invitrogen), as per manufacturer protocol. We used the let-
7c positive control as previously described [94]. Plasmid DNA was extracted as was 
previously described [94]. The 3’LIFE assay was performed as previously described [94, 
108]. In brief, 87 queried human 3’UTRs + 3 controls were transfected into HEK293T 
cells using the 96-well Shuttle nucleofection system (Lonza). Transfected cells were 
cultured for 72 hours and then lysed, then used to perform the dual luciferase assay. The 
screen was performed five times (435 reactions), and the resulting data was analyzed as 
previously described [94, 108]. The top hits for each miRNA were distinguished by 
requiring a minimum repression index of 0.8 and a p-value<0.05.   
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CHAPTER 3 
Identification of the tissue-specific targets of microRNAs 
using the model organism Caenorhabditis elegans 
 
Publication note 
The research reported in this chapter has been submitted for publication in Genetics. 
Kasuen Kotagama, Anna L Schorr, Hannah S Steber, and Marco Mangone. All co-
authors have granted permission for this work to be included in this dissertation. 
 
Overview 
Multicellular organisms have evolved complex forms of gene regulation achieved 
at different stages throughout development and equally executed at pre-, co-, and post-
transcriptional stages. Post-transcriptional gene regulation events mostly occur through 3’ 
Untranslated Regions (3’UTRs), which are portions of genes located between the STOP 
codon and the poly(A) tail of mature eukaryotic mRNAs. 3’UTRs have been recently 
subjected to intense study as they were found to be targeted by a variety of factors, which 
recognize small regulatory elements in these regions and can modulate the dosage of 
gene output at the post-transcriptional level [167-169]. While these regulatory 
mechanisms are still poorly characterized, and the majority of functional elements remain 
unknown, disorders in the 3’ end processing of mRNAs have been found to play critical 
roles in the loss of tissue identity and the establishment of prevalent diseases, including 
neurodegenerative diseases, diabetes, and cancer [51, 170-172]. 
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3’UTRs are frequently targeted by a class of repressive molecules named 
microRNAs (miRNAs). MiRNAs are short non-coding RNAs, ~22nt in length, that are 
incorporated into a large protein complex called the microRNA-induced silencing 
complex (miRISC), where they guide the interaction between the miRISC and the target 
mRNA by base pairing, primarily within the 3’UTR [173]. The outcome of miRNA 
targeting can be context-dependent. However, mRNAs targeted by the miRISC are 
typically held in translational repression before degradation of the transcript [15, 65]. 
Initial studies showed that although mismatches between miRNAs and their targets are 
common, many interactions make use of perfect complementarity at a small conserved 
hexametrical motif, located at position 2-7, at the 5’end of the miRNA (seed region), [15, 
65]. Later findings showed that while important, the seed region may also contain one or 
more mismatches while pairing with its target mRNA and that this element alone is not a 
sufficient predictor of miRNA targeting [91-93, 174]. Compensatory base pairing at the 
3ʹ end of the miRNA (nucleotides 10-13) can also play a role in target recognition [150, 
175], and have been implicated in conferring target specificity to miRNAs that share the 
same seed regions [11, 98]. 
MiRNAs and their 3’UTR targets are frequently conserved and play a variety of 
roles in modulating fundamental biological processes across metazoans. Bioinformatic 
algorithms, such as miRanda [101], TargetScan [95] and PicTar [96], use evolutionary 
conservation and thermodynamic principles to identify miRNA target sites and are the 
preferred tools for miRNA target identification. Based on these algorithms it was initially 
predicted that each miRNA controls hundreds of gene products [176]. Recent high-
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throughput wet bench approaches, have validated and expanded on these initial 
predictions, and provide further evidence that miRNAs can indeed target hundreds of 
genes, and regulate molecular pathways throughout development and in diseases [11, 22, 
94, 105, 177]. In the past few years, several groups produced tissue-specific miRNA 
localization data in mouse, rat, and human tissues [178, 179] and cancer [180].  
C. elegans is a small roundworm that is a well-characterized model organism to 
study post-transcriptional gene regulation. C. elegans, colloquially known as the worm, 
has a fully-annotated and cloned 3'UTRome [40, 181], and a lot is known about its RBP 
[182] and miRNA-based gene regulation [60]. The worm has a well-known, invariable 
cell lineage making it ideal for studying tissue development. In addition, our group has 
pioneered the use of C. elegans to study tissue-specific gene expression systematically 
[69, 158]. In a previous study, we developed a method to isolate and sequence high-
quality tissue-specific mRNA from worms and published several integrative analyses of 
gene expression in most of the C. elegans somatic tissues, including the intestine and 
body muscle [69, 158]. As a consequence, the worm is an unparalleled model for 
studying miRNA regulation where we have information concerning the tissue-specific 
genes, and 3’UTR isoforms expressed. 
A previous low-throughput study has identified hundreds of miRNAs and their 
targets in the intestine and body muscle of C. elegans, which are mostly involved in the 
immune response to pathogens [183]. This study used a microarray-based approach, 
which unfortunately does not provide enough depth to understand miRNA function in a 
tissue-specific manner fully. In addition, this study identified only a subset of miRNA 
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targets, which rely on the scaffolding proteins AIN-1 and AIN-2, later found to be only 
present at specific developmental stages [183, 184]. 
In C. elegans there are three Argonaute proteins execute the miRNA pathway and 
are named alg-1, alg-2, and alg-5. Recent transcriptome analysis in strains deficient in 
each of these members show a remarkable difference in function, where alg-1 and alg-2 
are mostly expressed in somatic tissue and are functionally redundant, while alg-5 is 
expressed exclusively in the gonads, interacts with only a subset of miRNAs and is 
required for optimal fertility [177]. A more recent study used a novel methylation-
dependent sequencing approach (mime-Seq) and identified high-quality tissue-specific 
miRNAs in the intestine and body muscle tissues [185]. These studies show that there are 
indeed distinct functional miRNA populations in tissues, which can potentially reshape 
transcriptomes and contribute to the acquisition and maintenance of cell identity. Since 
most miRNA targets are only predicted, it is still unclear how these events are initiated 
and maintained. 
To better understand the tissue-specific contribution of miRNA-based 
regulation to tissue identity, we isolated and sequenced the tissue-specific targets 
of miRNAs, from two of its largest and most well-characterized tissues in C. 
elegans, the intestine and body muscle. The total number of genes regulated in 
each tissue correlates with transcriptome size. However, more of the intestinal 
transcriptome is regulated when compared to the body muscle, suggesting that the 
degree of regulation by miRNA in tissues is heterogeneous.  
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We find that tissue-specific miRNA targets include genes that are 
important for development and genes that are involved with normal tissue 
function. MiRNAs are known to reduce gene expression at the protein level, as 
opposed to silencing or knocking out expression, and as such, it is reasonable that 
miRNAs would target tissue-specific genes to modulate their expression and 
contribute to tissue homeostasis. Using a bioinformatic analysis of the 3’UTRs of 
the tissue-specific targets we identify that APA, and the tissue-specific expression 
patterns of miRNAs appear to be driving forces of tissue-specific miRNA 
regulation. 
 
Results 
 
A method for the identification of tissue-specific miRNA targets 
To study the contribution of miRNA activity in producing and maintaining tissue 
identity, we performed RNA immunoprecipitations of miRNA target genes in two of the 
 
Figure 3.1 - The anatomical location of the two studied somatic tissues. We used 
the promoters of the intestine-specific gene ges-1(abnormal Gut ESterase) and the 
body muscle specific myo-3(MYOsin heavy chain structural genes) for the 
expression of tissue-specific constructs. 
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largest, morphologically different, and most well-characterized tissues in C. elegans: the 
intestine [186] and body muscle [187] (Figure 3.1).   
We took advantage of the ability of the Argonaute protein to bind miRNA target 
genes and cloned alg-1, one of the worms orthologs of the human Argonaute 2 protein, 
downstream of the green fluorescent protein (GFP). The expression of this construct was 
then driven by the endogenous promoter (alg-1p), or restricted to the intestine (ges-1p) or 
body muscle (myo-3p) using tissue-specific (TS) promoters (Figure 3.2). We produced 
 
Figure 3.2 - Workflow for the identification of tissue-specific miRNA targets. We 
cloned the C. elegans Argonaute protein alg-1 and fused it with the GFP fluorochrome 
and the unspecific unc-54 3’UTR. The expression of this cassette was driven in the 
intestine and body muscle by using tissue-specific (TS) promoters. These constructs 
were microinjected into MosSCI-compatible C. elegans strains to produce single-copy 
integrated transgenic animals. These strains were then subjected to UV crosslinking and 
lysed by sonication. The resulting lysate was subjected to RNA immunoprecipitations 
with α-GFP antibodies. The resultant tissue-specific miRNA target transcripts were 
purified, the cDNA libraries were made and sequenced using Illumina HiSeq. 
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transgenic strains for each construct (Figure 3.3) using single copy integration technology 
(MosSCI) [188, 189] to minimize the expression mosaics produced by repetitive 
extrachromosomal arrays. The strains were validated for integration using genomic PCRs 
and Western blots (Figure 3.4 and 3.5). 
We then examined the functionality of our cloned alg-1 in rescue experiments 
using the alg-1-/- strain RF54(gk214). This strain has a decrease in fertility caused by the 
loss of functional alg-1 [190], which was fully rescued by our cloned alg-1 construct in a 
brood size assay (Figure 3.6 and 3.7), suggesting that our cloned alg-1 is functional and 
able to mimic endogenous alg-1 fully. 
 
 
Figure 3.3 - Representative images of C. elegans single copy integrated strains. The 
expression of GFP tagged alg-1 in endogenous (alg-1p), intestine (ges-1p), body muscle 
(myo-3p) tissues. The yellow box indicated magnified regions, yellow arrows mark 
intestine cells, and red arrows mark body muscle cells. 
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Figure 3.4 - Agarose gel electrophoresis of PCR products obtained from 
genomic DNA a using single-worm PCR approach from transgenic C. 
elegans strains prepared in this study. Each strain was tested using primers that 
detect either the presence (+) or the absence (-) of the integrated MosSCI 
transgene. Red asterisks mark expected bands confirming integration of our 
constructs. 
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Figure 3.5 - Western blot experiments from wt N2 worms or strain expressing 
endogenous the ALG-1 pull-down construct. Immunoprecipitations were 
performed using either ⍺-GFP antibodies or unconjugated beads (UB) on 
immunoprecipitated protein obtained from each strain. (IP) Immunoprecipitated 
protein, (SN) supernatant. Red asterisk marks the expected band.
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Figure 3.6 – PCR to genotype and validate worm crosses to rescue alg-1 
expression in RF54 with transgenic gfp tagged alg-1. An agarose gel used to 
visualize single worm genomic PCRs testing the presence of the gk214 mutation 
before and after the cross. The yellow asterisks indicate the genomic locus with 
wt alg-1 (2,557bp). The green asterisks indicate gfp tagged transgenic alg-1. 
The red asterisks indicate the presence of the gk214 mutation (2,350bp). In the 
MMA20 strain, we re-introduced our cloned gfp tagged alg-1 to the RF54 strain, 
which lacks of endogenous alg-1.  
 
MMA17 RF54 MMA20
1k
gfpalg-1p
alg-1p gk214
alg-1p 2,557bp
3,480bp
2,350bp*
* *
*
* *
*
*
alg-1
alg-1
alg-1
 
Figure 3.7 - Results from a brood size assay testing fertility. The loss of 
fertility seen in the alg-1 knockout strain RF54 is rescued in the MMA20 strain 
which expresses our GFP tagged transgenic ALG-1, suggesting that our ALG-1 
pull-down construct is functional and mimic endogenous alg-1 activity. Student 
t-test. ** p<0.01. Error bars indicate the standard error of the mean. 
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We then used our strains to perform tissue-specific RNA immunoprecipitations. 
Each tissue-specific ALG-1 IP and control IPs were performed in duplicate using 
biological replicates (total 6 sequencing runs). We obtained ~25M reads on average for 
each tissue, of which ~80% were successfully mapped to the C. elegans genome 
(WS250) (Figure 3.8). To maximize our success, we used very stringent filters to 
determine gene presence, using only the top 25-50% of genes mapped in each dataset 
(Figure 3.9) (Materials and Methods) [56, 191]. Our analysis resulted in 3,681 different 
protein-coding genes targeted by the miRISC using the endogenous alg-1 promoter or in 
the intestine or body muscle.  
There are only 27 validated C. elegans miRNA-target interactions with strong 
evidence reported in the miRNA target repository miR-TarBase v7, and our study 
confirmed 16 of these interactions (59%), which is threefold enrichment when compared 
to a random dataset of similar size (p<0.05, chi-square test) (Figure 3.10). 
 
 
Figure 3.8 - Overview of the sequencing reads obtained for each 
immunoprecipitation. Each sample was sequenced in duplicate with biological 
replicates. We obtained at least 15M reads each dataset mapped to the C. elegans 
genome (WS250). 
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Figure 3.9 - In this study we have used only the top ~50-75% positive hits 
produced by the Cufflinks algorithm. Blue; Body muscle. Red; Intestine C) Principal 
Component Analysis (PCA) between the median FPKM values among replicates shows 
differences between tissues within our datasets. Each dot represents a median 
experiment and replicate. 
 
 
Figure 3.10 - Venn diagram showing the comparison of the genes identified in 
this study to miR-TarBase v7, a compendium of all experimentally validated 
miRNA targets. 59% of the genes in this database match those identified in this 
study. There is a 3-fold enrichment of miRNA targets, based on a Chi-squared test 
comparing to a random data-set of the same size *p<0.05. 
 
113,665
Cumulative
16*
(59%)
miR-Tarbase v7
This study
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When compared to genes present in the C. elegans intestine and body muscle 
transcriptomes [56], 81% of the intestine and 56% of the body muscle targets identified 
in this study match with their respective tissues (Figure 3.11). A comparison between our 
hits and a previously published ALG-1 IP dataset in all tissues also support our results 
(Figure 3.13) [106]. To further validate the quality of our hits, we used GFP-based 
approaches to confirm the tissue localization of a few tissue-specific genes identified in 
our study and found that except one, their observed localization matches the expected 
tissue (Figure 3.12). In addition, to further test the quality of our data, we compared our 
results with the intestine and body muscle-specific miRNA localization data from past 
studies [185] (Figure 3.13). We found that more than 84% of the genes identified in our 
study possess predicted binding sites in their 3’UTRs for miRNAs detected in each tissue, 
suggesting a strong correlation between our results and Alberti et al., 2018 [185] (Figure 
3.14).   
 
 
Figure 3.11 - Venn diagram showing the comparison of the genes identified in 
this study to previously published tissue-specific intestine and body muscle 
transcriptomes. The majority of the targets in both datasets were previously 
assigned to each tissue. Green – Intestine (ges-1p). Blue – Body muscle (myo-3p). 
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Figure 3.12 - Validation of tissue localization selected hits detected in our 
tissue-specific ALG-1 pull-down. We have cloned selected promoters from genes 
identified in our tissue-specific ALG-1 pull-down and fused it to GFP reporters to 
validate the expression localization pattern. Except for one case, we detected 
strong GFP expression in the expected tissues.  The red arrow marks intestine 
expression, the yellow arrow marks body muscle expression. Putative expression 
index: 
 - not detected; * low expression; ** expressed; *** strong expression 
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Figure 3.13 - Comparison of our tissue-specific ALG-1 pull-down to previously 
identified whole worm ALG-1 targets (Zisoulis et al., 2010). Venn diagram 
showing the comparison of hits between our datasets and a whole-worm RNA pull-
down of ALG-1 targets. 
  
 
Figure 3.14 - Comparative analysis of our tissue-specific ALG-1 pull-down to 
previously identified intestine and body muscle miRNA (mime-seq) (Alberti et 
al., 2018). The left pie chart shows the percentage of genes identified in our study 
with predicted miRNA binding sites as for MiRanda algorithm. The right pie chart 
shows how many of those genes contain a seed region for intestine or body muscle 
miRNAs identified in Alberti et al., 2018. The tables show how many genes 
identified in our study are targeted by unique tissue-specific miRNAs identified in 
Alberti et al., 2018. The bar charts show the percentage of total and tissue-restricted 
(unique) intestine or body muscle ALG-1 targeted genes identified in our study with 
seed regions for miRNAs identified in Alberti et al., 2018  
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ALG-1 targets in the intestine regulate key metabolic enzymes 
The C. elegans intestine is composed of 20 cells that begin differentiation 
early in embryogenesis and derive from a single blastomere at the 8-cell stage 
[186]. As the primary role of the intestine is to facilitate the digestion and the 
absorption of nutrients, many highly expressed genes in this tissue are digestive 
enzymes, ion transport channels and, regulators of vesicle transport [186].  
In our intestinal ALG-1 pull-down, we identified 3,089 protein-coding 
genes targeted by miRNAs. 2,367 of these genes were uniquely targeted by 
miRNAs in this tissue (Figure 3.15). As expected, and consistent with the 
function of the intestine, we find many enzymes involved with glucose 
metabolism, such as enol-1 an enolase, ipgm-1 a phosphoglycerate mutase, and 3 
out of 4 glyceraldehyde-3-phosphate dehydrogenases (gpd-1, gpd-2, and gpd-4). 
The human orthologue of the C. elegans gene enol-1, ENO1 has been previously 
identified as a target of miR-22 in the context of human gastric cancer [192]. In 
addition, some of our top hits are the fatty acid desaturase enzymes fat-1, fat-2, 
fat-4 and fat-6, which are all involved with fatty acid metabolism, suggesting that 
these metabolic pathways are subjected to a high degree of regulation in the 
intestine. All of these genes contain seed elements in their 3’UTRs. Additionally, 
we find 5 out of 6 vitellogenin genes (vit-1, vit-2, vit-3, vit-5 and vit-6) strongly 
targeted by miRNAs, with vit-2 and vit-6 being the most abundant transcripts in 
our immunoprecipitation. vit-2 was shown to be targeted by ALG-1 in a previous 
study [183], and both possess MiRanda [99, 101] and/or PicTar [96] predicted 
  62 
binding sites . These vitellogenin genes produce yolk proteins and are energy 
carrier molecules synthesized in the intestine. These yolk proteins are then 
transported to the gonads and into the oocytes to act as an energy source for the 
developing embryos [193]. Accordingly, we also find some RAB family proteins 
that are responsible for intracellular vesicular transport (rab-1, rab-6.1, rab-7, 
rab-8, rab-21, rab-35 and rab-39). 
Several transcription factors were also identified as miRNA targets in the 
intestine. skn-1 is a bZip transcription factor that is initially required for the 
specification of cell identity in early embryogenesis, and then later plays a role in 
modulating insulin response in the intestine of adult worms [194]. This gene has 
already been found to be targeted by miRNA in many past studies [106, 183] and 
contains many predicted miRNA binding sites and seed regions from both 
MiRanda [99, 101] and PicTar [96] prediction software. A second transcription 
factor pha-4 is expressed in the intestine, where it affects dietary restriction 
mediated longevity [195]. pha-4 is a validated target of let-7 in the intestine[196], 
and along with skn-1, is also targeted by miR-228 [195]. Additionally, pha-4 is 
targeted by miR-71 [195]. 
We also find as a target of miRNA, die-1 a gene which associated with the 
attachment of the intestine to the pharynx and the rectum [197], and the chromatin 
remodeling factor lss-4 (let seven suppressor), which is able to prevent the lethal 
phenotype induced by knocking out the miRNA let-7 [196]. Others have also 
validated these miRNAs as targets [196]. 
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In C. elegans the intestine produces an innate immune response to pathogens. The 
genes atf-7, pmk-1 and sek-1 were all identified as targets of miRNAs in this tissue. 
These three genes act together to produce a transcriptional innate immune response where 
the transcription factor atf-7 is activated through phosphorylation by kinases pmk-1 and 
sek-1. Consistent with our findings, the role of miRNAs in regulating the innate immune 
response through the intestine and these genes has been reported in multiple studies [183, 
198, 199]. 
 
Muscle ALG-1 targets modulate locomotion and cellular architecture 
C. elegans possess 95 striated body wall muscle cells, which are essential 
for locomotion [187]. Its sarcomeres are composed of thick filaments containing 
myosin associated with an M-line, and thin filaments containing actin associated 
with the dense body. The pulling of actin filaments by myosin heads generates a 
force that produces locomotion [200]. 
Our ALG-1 pull-down identified 1,047 protein-coding genes targeted by 
miRNAs in the body muscle tissue (Figure 3.15). Within this group, 348 genes 
were not present in our intestine dataset, and are specifically restricted to the body 
muscle tissue. Our top hits include genes involved in locomotion, and general 
DNA maintenance (grd-5, gcc-1, gop-2, etc.) and several with unknown function. 
Consistent with muscle functions, we detected mup-2, which encodes the muscle 
contractile protein troponin T, myo-3, which encodes an isoform of the myosin 
heavy chain, dlc-1, which encodes dynein light chain 1 and F22B5.10, a poorly 
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characterized gene involved in striated muscle myosin thick filament assembly. 
mup-2, myo-3 and dlc-1 were all found to be targeted by ALG-1 in previous 
studies [106, 183]. Consistent with muscle function, a GO term analysis of this 
dataset highlights an enrichment of genes involved in locomotion, suggesting a 
potential role for miRNAs in this biological process. 
We also identified numerous actin gene isoforms (act-1, act-2, act-3 and 
act-4), which are required for maintenance of cellular architecture within the body 
wall muscle, and the Rho GTPase rho-1, which is required for regulation of actin 
filament-based processes including embryonic polarity, cell migration, cell shape 
changes, and muscle contraction. Small GTPase are a gene class heavily targeted 
by miRNAs [201, 202]. The human ortholog of rho-1 is a known target for miR-
31, miR-133, miR-155 and miR-185 [202]. 
Importantly, we also found several muscle-specific transcription factors 
including mxl-3, a basic helix-loop-helix transcription factor, and K08D12.3, an 
ortholog of the human gene ZNF9. These genes are known to regulate proper 
muscle formation and cell growth. mxl-3 is targeted by miR-34 in the context of 
stress response [203]. Both genes have been detected in past ALG-1 
immunoprecipitation studies [106]. 
Our top hit in this tissue is the zinc finger CCCH-type antiviral gene pos-1, a 
maternally inherited gene necessary for proper fate specification of germ cells, intestine, 
pharynx, and hypodermis[204]. pos-1 contains several predicted miRNA binding sites in 
its 3’UTR, and based on our GFP reporter validation study is strongly expressed in the 
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body muscle (Figure 3.13). We also find the KH domain containing protein gld-1, the 
homolog of the human gene QKI, which is targeted by miR-214 [205], miR-200c and 
miR-375 [206]. 
 
miRNA targeting is more extensive in the intestine than it is in the body muscle  
By comparing the percentage of tissue-specific miRNA targets identified in our 
study to the previously published intestine and body muscle transcriptomes [56, 191], we 
found that the hits in the intestine are almost twice the number of hits we obtained in the 
body muscle tissue (30.3% vs 18.2%) (Figure 3.15).  
The length of the 3`UTRs of genes identified as miRNA targets in the intestine 
and the body muscle tissues are similar when comparing the two tissues, but are on 
average longer and have more predicted miRNA binding sites than the overall C. elegans 
transcriptome (Figure 3.16). Our results indicate that despite the similarity in average 
3’UTR length in tissues.  In this specific case, we found that the intestine utilizes 
miRNA-based gene regulation to a greater extent when compared with the body muscle. 
 
 
Figure 3.15 – Unique miRNA targets in each tissue correspond to tissue-specific 
functions. Pie chart showing the proportion of miRNA targets detected in this study 
compared to tissue-specific transcriptomes previously characterized by Blazie et.al 2017. 
The Venn diagram in the center shows the number of protein-coding genes identified in 
this study as miRNA targets between the intestine and body muscle. The tables show a 
Gene Ontology analysis for pathway enrichment using the top 100 genes from each 
dataset used in this study.  Green – Intestine (ges-1p). Blue – Body muscle (myo-3p). 
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Figure 3.16 - The length of 3’UTRs from protein-coding genes as from the 
3’UTRome v1 (MANGONE et al. 2010) compared to the intestine and body 
muscle targets identified in this study. The arrows indicate the median 3`UTR 
length. Genes targeted in the intestine and body muscle have longer 3`UTRs on 
average than those published in the C. elegans 3`UTRome v1.  
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Figure 3.17 - Proportion of 3`UTRs with predicted miRNA binding sites 
miRanda and PicTar (LALL et al. 2006; BETEL et al. 2008) in the 3`UTRome 
(gray), when compared to the 3’UTRs of genes identified in this study.  Green – 
Intestine; Blue – Body muscle. The genes identified in this study in the intestine 
and body muscle are enriched for predicted miRNA binding sites. 
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MiRNA targets in the intestine and body muscle are enriched for miR-355 and miR-85 
binding sites 
 Bioinformatic analysis of the longest 3`UTR isoforms of the targeted genes 
showed there was no specific requirement for the seed regions in either tissue (Figure 
3.18). However, the use of predictive software showed that in addition to others, there is 
an intestine-specific bias for miR-355 targets (Figure 3.18). This miRNA is involved in 
the insulin signaling and innate immunity [207], which in C. elegans are both mediated 
through the intestine. 
In contrast, we observed an enrichment of targets for the poorly characterized 
miR-85 in the body muscle dataset (Figure 3.18). These two miRNAs are uniquely 
expressed in the respective tissues [208]. While miR-85 and miR-355 were the most 
abundant and tissue-restricted miRNAs identified in this study, several other miRNAs, 
including miR-71, miR-86, miR-785 and miR-792 were also found highly expressed but 
less spatially restricted. 
 
Figure 3.18 - Analysis of miRNA target sites identified in this study. The two-
axis show the proportion of 3ʹUTRs with perfect seeds or with predicted target sites 
(miRanda) (BETEL et al. 2008), normalized to the total number of genes targeted in 
each tissue for each miRNA. miRNAs that target more than 2% of the genes are 
listed. The blue mark denotes miR-85, a body muscle-specific miRNA. The green 
mark denotes miR-355, an intestine-specific miRNA. 
0
2
4
0 2 4
B
o
d
y
 m
u
s
c
le
 (
%
)
Intestine (%)
seed presence
miR-5550
miR-2
miR-70
0
2
4
0 2 4
B
o
d
y
 m
u
s
c
le
 (
%
)
Intestine (%)
predicted binding sites
miR-71
miR-792 miR-785
miR-86
miR-355
miR-85
  68 
Discussion 
 
We have developed tools to identify in vivo tissue-specific targets of miRNAs in C. 
elegans 
In this study, we have developed tools and techniques to identify tissue-
specific miRNA targets and applied them to uniquely define the genes targeted by 
miRNAs in the C. elegans intestine and body muscle. We validated previous 
findings and mapped ~3,000 novel tissue-specific interactions (Figure 3.10-3.12).  
To perform these experiments, we have prepared worm strains expressing 
ALG-1 fused to GFP and expressed this cassette in the intestine and body muscle 
using tissue-specific promoters. We validated the ALG-1 expression (Figure 3.3- 
3.5), and the viability of our ALG-1 construct in in vivo studies (Figure 3.6 and 
3.7). We have then performed ALG-1 immunoprecipitations in duplicate, 
separated the miRNA complex from their targets, and sequenced the resultant 
RNA using Illumina sequencing (Figure 3.2 and 3.8). To confirm our results, we 
validated a few selected hits with expression localization studies in both tissues 
(Figure 3.13). Importantly, our ALG-1 pull-down results agree with previous 
studies (Figure 3.10-3.12, and 3.14), and are significantly enriched with predicted 
miRNA targets (Figure 3.17).  
We have uploaded our intestine and body muscle miRNA target datasets 
into the 3’UTRome database (www.UTRome.org), which is the publicly available 
resource for the C. elegans community interested in 3’UTR biology [40, 181]. In 
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order to provide a more comprehensive overview, we have also manually curated 
and included results from several available datasets including PicTar [96] and 
TargetScan [95] miRNA target predictions, experimentally validated ALG-1 
interaction [106, 183], tissue-specific gene expression and expanded 3’UTR 
isoform annotation data [56, 75, 191].  
 
The level of miRNA-based gene regulation is heterogeneous across tissues.   
The genes identified in this study overall match with the intestine 
transcriptome previously published by our group (81%) [56, 191]. Of note, only 
56% of genes identified as miRNA targets in the body muscle match the body 
muscle transcriptome (Figure 3.15). Perhaps, the remaining targets are genes 
strongly down-regulated by miRNAs in this tissue, leading to rapid deadenylation 
and mRNA degradation that make them undetectable using our PAB-1-based 
pull-down approach. Given the fact the body muscle transcriptome is significantly 
smaller than the intestine transcriptome, it may also be subjected to less regulation 
through miRNA. However, if we normalize the number of genes expressed in 
each tissue and study the proportion of the transcriptome targeted by miRNA, we 
still find significantly more regulation in the intestine (Figure 3.15), suggesting 
that this tissue may indeed employ miRNA-based gene regulation to a greater 
extent. 
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MiRNAs regulate tissue-specific targets to contribute to homeostasis. 
The majority of the targeted genes in our intestine pull-down are unique to 
the intestine and share only a handful of genes with our body muscle dataset (725 
genes, 23% of the total intestine dataset) (Figure 3.15). Many of the genes 
uniquely targeted by miRNAs in each tissue correspond to the functions of that 
tissue (Figure 3.15). The intestine of the worm is involved with a variety of 
functions throughout its life. From hatching, the intestine is responsible for 
metabolism, vesicle transport, and mounting innate immune response but upon 
reaching the adult stage, the intestine also plays an important role in regulating 
fertility. Accordingly, we find genes uniquely targeted by miRNAs in the intestine 
that are a part of each of these pathways. In the case of the body muscle, very few 
genes are uniquely targeted, but yet show an enrichment for genes involved with 
locomotion and cellular architecture. The importance of miRNAs in development 
is well established, however this pattern of targeting genes that are important for 
normal tissue function suggests that miRNAs also contributes to the maintenance 
of these tissues. The small pool of shared genes between both tissues includes 
housekeeping genes that are most likely regulated similarly in both tissues. Of 
note, this minimal overlap between our tissue-specific datasets indicates that our 
ALG-1 pull-down is indeed tissue-specific with marginal cross-contamination. 
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Precise tissue-specific miRNA targeting relies on principles outside of target site 
availability  
We hypothesized that the binding sites for tissue-specific miRNAs would 
be more abundant in the 3’UTRs of tissue-specific targets. To test this hypothesis, 
we performed a bioinformatic analysis of predicted miRNA binding sites and seed 
availability in the longest 3’UTR isoforms of genes in our ALG-1 IPs.  
We found binding sites for tissue-specific miRNAs in the 3’UTRs of our targets, 
which is in agreement with miRNA localization datasets [185] (Figure 3.14). 
However, the binding sites for these miRNAs are not more abundant than the 
binding sites of other miRNAs.  
A majority of miRNAs are predicted to target less than 2% of the 3’UTRs 
identified in our IPs (Figure 3.18), which is intriguing as it suggests that the 
availability of predicted miRNA binding sites and seed regions are poor indicators 
of targeting by miRNAs, and indicates that mechanisms such as APA and tissue-
specific miRNA expression patterns modulate precise miRNA-based gene 
regulation. 
The exceptions to this observation are the miRNAs miR-71, miR-86, miR-
785, miR-792, miR-85 and miR-355, which have predicted binding sites in more 
than 2% of the 3’UTRs of the targets isolated from each tissue. Very little is 
known about most of these miRNAs. However, miR-355 is uniquely expressed in 
the intestine and miR-85 is uniquely expressed in the body muscle and both 
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miRNAs show a slight enrichment of binding sites of the targets from the 
corresponding tissue. 
Our experimental approach was designed for tissue-specific mRNA target 
identification and unfortunately did not provide miRNA data. We assign tissue-
specific targets to miRNAs relying primarily on prediction software and 
correlation to past-published datasets. These comparative approaches required 
conversion between genomic releases and data consolidation across different 
developmental stages and conditions, which may have added unwanted variability 
to our comparative analysis. Overall, the results from this study highlight 1) A 
method for the in vivo identification of tissue-specific targets of miRNA. 2) The 
tissue-specific roles of miRNAs in regulating gene expression, especially in 
regards to tissue development and homeostasis. 3) Provides insights on the 
mechanisms that influence tissue-specific miRNA targeting. 
 
Experimental 
 
Preparing MosSCI vectors for generating GFP::ALG-1 strains 
The strains used for the ALG-1 pull-down were prepared using a modified 
version of the previously published polyA-pull construct [56, 191]. We produced 
a second-position Entry Gateway vector containing the genomic sequence of alg-
1 tagged at its N-terminus with the GFP fluorochrome. Briefly, we designed 
primers flanking the coding sequence of alg-1 and performed a Polymerase Chain 
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Reaction (PCR) amplification to clone the alg-1 locus from genomic DNA 
extracted from N2 wt worms (primer 1 and 2 in Table 3.1). The resulting PCR 
product was analyzed on a 1% agarose gel, which displayed a unique expected 
band at ~3,500 nucleotides. This band was then isolated using the QIAquick Gel 
Extraction Kit (QIAGEN, cat. 28704) according to the manufacturer’s protocol. 
Upon recovery, we digested the purified PCR product with the restriction 
enzymes SacI and BamHI and then cloned it into the modified polyA-pull 
construct [56, 191], replacing the gene pab-1. The ligation reaction was 
performed using the NEB Quick Ligation Kit (cat. MS2200S) according to the 
manufacturer’s protocol. We used the QuikChange II Site-Directed Mutagenesis 
Kit (Agilent, cat. 200523) to remove the unnecessary C-terminal 3xFLAG tag 
from the polyA-pull vector (primers 3 and 4 in Table 3.1). We then cloned the 
previously described endogenous alg-1 promoter [209] by designing primers to 
add Gateway BP cloning elements and then performed PCR using N2 wt genomic 
DNA as a template (primers 5 and 6 in Table 3.1). Using the resulting PCR 
product, we performed a Gateway BP cloning reaction into the pDONR P4P1R 
vector (Invitrogen) according to the manufacturer’s protocol. To assemble the 
final injection clones, we performed several Gateway LR Clonase II plus 
reactions (Invitrogen, cat. 12538-013) using the destination vector CFJ150 [188], 
the tissue-specific or endogenous promoters (alg-1 for endogenous, ges-1 for the 
intestine and myo-3 for the body muscle), the gfp tagged alg-1 coding sequence, 
and the unc-54 3’UTR as previously published[56].  
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Microinjections and screening of transgenic C. elegans strains 
To prepare single copy integrated transgenic strains we used the C. 
elegans strain Eg6699 [ttTi5605 II; unc-119(ed3) III; oxEx1578][188], which is 
designed for MosI mediated single copy integration (MosSCI) insertion, using 
standard injection techniques. These strains were synchronized by bleaching[210], 
then grown at 20oC for 3 days to produce young adult (YA) worms. YA worms 
were then picked and subjected to microinjection using a plasmid mix containing; 
pCFJ601 (50ng/μl), pMA122 (10ng/μl), pGH8 (10ng/μl), pCFJ90 (2.5ng/μl), 
pCFJ104 (5ng/μl) and the transgene (22.5ng/μl)[211]. Three injected worms were 
isolated and individually placed into single small nematode growth media (NGM) 
plates (USA Scientific, cat 8609-0160) seeded with OP50-1 and were allowed to 
grow and produce progeny until the worms had exhausted their food supply. The 
plates were then screened for progenies that exhibited wild type movement and 
proper GFP expression, and single worms exhibiting both markers were picked 
and placed onto separate plates to lay eggs overnight. In order to select for single 
copy integrated worms, an additional screen was performed to select for worms 
that lost the mCherry fluorochrome expression (extrachromosomal injection 
markers). 
 
Genotyping of transgenic C. elegans strains 
Single adult worms were isolated and allowed to lay eggs overnight and 
then genotyped for single copy integration of the transgene by single worm PCR 
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as previously described [98] (primers 7-9 in Table 3.1). Progeny from worms that 
contained the single copy integrations were propagated and used for this study. A 
complete list of worm strains produced in this study is shown in Table 3.2. 
 
Validating expression of the transgenic construct 
To validate the expression of our transgenic construct, and to evaluate our ability 
to immunoprecipitate GFP tagged ALG-1, we performed immunoprecipitation (as 
described below) followed by a western blot. For the western blot we used a primary anti-
GFP antibody (Novus, NB600-303) (1:2000) and a fluorescent secondary antibody (LI-
COR, 925-32211)(1:5000), followed by imaging using the ODYSSEY CLX system (LI-
COR Biosciences, NE) (Figure 3.5).  
 
In vivo validation of GFP::ALG-1 functionality by brood size assay 
In order to validate the in vivo functionality of our transgenic GFP tagged 
ALG-1, we used a genetic approach. It was previously shown that the knock out 
alg-1 strain RF54 [alg-1(gk214) X] lead to a decrease in fertility [190]. We 
rescued this decrease in fertility in the alg-1 knockout strain RF54[alg-1(gk214) 
X] by crossing it into our strain MMA17 (Table 3.2), which expresses our GFP 
tagged transgenic ALG-1, driven by the endogenous alg-1 promoter. The 
resulting strain MMA20 [alg-1(gk214)X; alg-1p::gfp::alg-1::unc-54 II] only 
expresses our cloned alg-1 gene tagged with the GFP fluorochrome. We validated 
the genotype of MMA20 using single worm PCRs as previously described[98] 
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(primers 10 and 11 in Table 3.1 and Figure 3.6). The brood size assay was used to 
evaluate the ability of our transgenic GFP tagged ALG-1 construct to rescue the 
loss in fertility seen in the alg-1 knockout strain (RF54). The brood size assay was 
performed by first synchronizing N2 (wt), RF54 and MMA20 strains to arrested 
L1 larvae, through bleaching followed by starvation overnight in M9 solution. We 
then plated the L1 arrested worms on NGM plates seeded with OP50-1 and 
allowed the worms to develop to the adult stage for 48 hours after which single 
worms were isolated onto OP50-1 seeded plates. The adult worms were left to lay 
eggs overnight (16 hours) after which the adult worms were removed. The eggs 
were allowed to hatch and develop for 24 hours, and the number of larvae in each 
plate was counted.   
 
Sample preparation and crosslinking 
0.5ml of mixed stage C. elegans of each strain was grown on five large 20 
cm plates (USA Scientific, cat 8609-0215) and harvested by centrifugation at 
400rcf for 3 minutes. The pellets were initially washed in 15ml dH2O water and 
spun down at 400 rcf for 3 minutes and then resuspended in 10ml of 
M9+0.1%Tween20 and then cross-linked 3 times on ice, with energy setting: 
3000 x 100 μJ/cm2 (3kJ/m2) (Stratalinker 2400, Stratagene)[212]. After the 
crosslinking, each C. elegans strain was recovered by centrifugation at 400 rcf for 
3 minutes, and resuspended in two volumes (1ml) of lysis buffer (150mM NaCl, 
25mM HEPES(NaOH) pH 7.4, 0.2mM DTT, 10% Glycerol, 25 units/ml of 
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RNasin® Ribonuclease Inhibitor (Promega, cat N2611), 1% Triton X-100 and 1 
tablet of protease inhibitor for every 10ml of lysis buffer (Roche cOmplete 
ULTRA Tablets, Sigma, cat 5892791001). The lysed samples were subjected to 
sonication using the following settings: amplitude 40%; 5x with 10sec pulses; 
50sec rest between pulses (Q55 Sonicator, Qsonica). After the sonication, the cell 
lysate was cleared of debris by centrifugation at 21,000rcf at 4°C for 15 min and 
the supernatants were then transferred to new tubes.  
 
GFP-TRAP bead preparation and immunoprecipitation  
25μl of GFP-TRAP beads (Chromotek, gtma-10) (total binding capacity 
7.5μg) per immunoprecipitation were resuspended by gently vortexing for 30 
seconds, and washed three times with 500μl of cold Dilution/Wash buffer (10 
mM Tris/Cl pH 7.5; 150 mM NaCl; 0.5 mM EDTA). The beads were then 
resuspended in 100μl/per IP of Dilution/Wash buffer. 100μl of resuspended beads 
were then incubated with 0.5ml of lysate for 1 hour on the rotisserie at 4oC. At the 
completion of the incubation step, the beads were collected using magnets. The 
unbound lysate was saved for PAGE analysis. The beads containing the 
immunoprecipitatred alg-1 associated to the target mRNAs were then washed 
three times in 200μl of Dilution/Wash buffer (10 mM Tris/Cl pH 7.5; 150 mM 
NaCl; 0.5 mM EDTA), and then the RNA/protein complex was eluted using 
200μl of Trizol (Invitrogen, cat 15596026) and incubated for 10 minutes at room 
temperature. 
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Trizol/Driectzol RNA purification 
The RNA purification was performed using the RNA MiniPrep kit (Zymo 
Research, cat ZR2070) as per the manufacturer’s protocol. All centrifugation 
steps were performed at 21,000g for 30 seconds. We added an equal volume of 
ethanol (95-100%) to each sample in Trizol and mixed thoroughly by vortexing (5 
seconds, level 10). The samples were then centrifuged, recovered using a magnet, 
and the supernatant was transferred into a Zymo-Spin IIC Column in a Collection 
Tube and centrifuged. The columns were then transferred into a new collection 
tube and the flow through were discarded. 400 µl of RNA wash buffer was added 
into each column and centrifuged. In a separate RNase-free tube, we added 5 µl 
DNase I (6 U/µl) and 75 µl DNA Digestion Buffer, mixed and incubated at room 
temperature (20-30°C) for 15 minutes. 400 µl of Direct-zol RNA PreWash (Zymo 
Research, cat ZR2070) was added to each sample and centrifuged twice. The 
flow-through was discarded in each step. 700 µl of RNA wash buffer was then 
added to each column and centrifuged for 2 minutes to ensure complete removal 
of the wash buffer. The columns were then transferred into RNase-free tubes, and 
the RNAs were eluted with 30 µl of DNase/RNase-Free Water added directly to 
the column matrix and centrifuging. 
 
cDNA library preparation and sequencing 
Each cDNA library was prepared using a minimum of 500pg of 
immunoprecipitated RNA from each tissue. The total RNA was reverse transcribed using 
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the IntegenX’s (Pleasanton, CA) automated Apollo 324 robotic preparation system using 
previously optimized conditions[191]. The cDNA synthesis was performed using a SPIA 
(Single Primer Isothermal Amplification) kit (IntegenX and NuGEN, San Carlos, 
CA)[213]. The cDNA was then sheared to approximately 300 bp fragments using the 
Covaris S220 system (Covaris, Woburn, MA). We used the Agilent 4200 TapeStation 
instrument (Agilent, Santa Clara, CA) to quantify the abundance of cDNAs and calculate 
the appropriate amount of cDNA necessary for library construction. Tissue-specific 
barcodes were then added to each cDNA library, and the finalized samples were pooled 
and sequenced using the HiSeq platform (Illumina, San Diego, CA) with a 1x75bp HiSeq 
run. 
 
Data analysis 
We obtained ~15M unique reads per sample (~130M reads total). The 
software Bowtie 2 [214] run using default parameters was used to perform the 
alignments to the C. elegans genome WS250. We used custom Perl scripts and 
Cufflinks [215] algorithm to study the differential gene expression between our 
samples. A summary of the results is shown in (Figure 3.8-3.9). Mapped reads 
were further converted into a bam format and sorted using SAMtools software run 
with generic parameters [216], and used to calculate Fragments Per Kilobase 
Million (FPKM) values, as an estimate of the abundance of each gene per sample. 
We used an FPKM ≥ 1 on the median from each replicate as a threshold for 
identifying positive hits. This stringent approach discarded ~50-75% of mapped 
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reads for each sample (Figure 3.9). The quality of our finalized list of target genes 
was tested using a principal component analysis versus our N2 wt negative control 
(Figure 3.9).  
 
Molecular cloning and assembly of the expression constructs 
The promoters of candidate genes were extracted from genomic DNA 
using genomic PCR and cloned into Gateway-compatible entry vectors 
(Invitrogen). We designed Gateway-compatible primers (primers 12-19 in Table 
3.1) targeting 2,000 bp upstream of a given transcription start site, or up to the 
closest gene. Using these DNA primers, we performed PCRs on C. elegans 
genomic DNA, amplified these regions, and analyzed the PCR products by gel 
electrophoresis. Successful DNA amplicons were then recombined into the 
Gateway entry vector pDONR P4P1R using Gateway BP Clonase reactions 
(Invitrogen). The reporter construct pAPAreg has been previously described in 
Blazie et al., 2017 [56]. The coding region of this construct was prepared by 
joining the coding sequence of the mCherry fluorochrome to the SL2 splicing 
element found between the gpd-2 and gpd-3 genes, and to the coding sequence of 
the GFP gene. The entire cassette was then PCR amplified with Gateway-
compatible primers and cloned into pDONR P221 by Gateway BP Clonase 
reactions (Invitrogen).  
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Bioinformatic analysis of tissue-specific miRNA targeting biases 
The tissue-specific miRNA studies were performed in two steps. First, we utilized 
custom-made Perl scripts to scan across the longest 3ʹUTR of each C. elegans protein-
coding gene (WS250) in our datasets, searching for perfect sequence complementarity to 
the seed regions of all C. elegans miRNAs present in the miRBase database (release 21) 
[63, 218-221]. This result was then used to calculate the percentage of seed presence in 
the intestine and body muscle datasets. To calculate the percentage of predicted targets, 
we extracted both predicted target genes, and their target miRNA name from the 
miRanda database [101] and compared the results with our study.  
 
Comparison with other datasets 
We extracted the WormBase IDs of genes in the intestine and body muscle 
transcriptomes previously published by our group [56], and most abundant miRNA 
targets (transcript names) identified by Kudlow et al., 2012 in these tissues [183]. We 
then translated the transcript names from Kudlow et al., 2012 into WormBase IDs using 
custom Perl scripts, and compared how many genes in each of these groups overlap with 
our ALG-1 pull-downs. The results are shown in Figure 3.13. For the analysis shown in 
Figure 3.14 we extracted the names of the miRNAs previously identified by Alberti et al., 
2018 in the C. elegans intestine and body muscle tissues [185]. We then used custom Perl 
scripts to search for the presence of the seed regions of these miRNAs in the 3’UTRs of 
the genes identified in this study (Figure 3.1
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Table 3.1 – Primers used in Chapter 3. 
 
 
 
 
 
Primer 
# 
Primer Name Primer sequence 
1 alg1Ext_fwd 
AACGAGCTCTCCGGCGGGCCGCAATATTTGCCAGGAGTC
ATGAATTC 
2 alg1Ext_rev 
AACGGATCCAGCAAAGTACATGACGTTGTTGGCATCCGG
ATGAACC 
3 
3xFLAG del 
CALF F 
GCCAACAACGTCATGTACTTTGCTTAACATGTGAATTCGT
ATAGATCTCACCCAGCTTTC 
4 
3xFLAG del 
CALF R 
GAAAGCTGGGTGAGATCTATACGAATTCACATGTTAAGC
AAAGTACATGACGTTGTTGGC 
5 alg-1p_Fwd 
GGGGACAACTTTGTATAGAAAAGTTG 
GCTAATTATTTCTAGGTACTATATATTTG 
6 alg-1p_Rev 
GGGGACTGCTTTTTTGTACAAACTTG 
TGGGTCGTTTGAGGCGACG 
7 F_Universal GAGGCAGAATGTGAACAAGACTCGAGC 
8 R_Yes_N CTTTGAGCCAATTCATCCCGG 
9 R_No CCACGCCCAGGAGAACACGTTAG 
10 alg-1 start F ATGTCCGGCGGGCCG 
11 alg-1 exon2 R CCAGGTAATTGTCCCGGTGC 
12 
attB4_Peef-
1A.1_F 
GGGGACAACTTTGTATAGAAAAGTTGCTTCCATTGTTTCT
GTTAAATTAATGAAT 
13 
attB1r_Peef-
1A.1_R 
GGGGACTGCTTTTTTGTACAAACTTGTGGCTGCTACGGA
GTGAGC 
14 
attB4_Phsp-
1_F 
GGGGACAACTTTGTATAGAAAAGTTGAAATTTCATTTCT
TTTTTATAAATACTTCGGC 
15 
attB1r_Phsp-
1_R 
GGGGACTGCTTTTTTGTACAAACTTGTTTTTACTGTAAAA
AATAATTTAAAAATCAAGAAAT 
16 
attB4_Ppos-
1_F 
GGGGACAACTTTGTATAGAAAAGTTGCCCAAATACCATT
TTGAAACTGAATC 
17 
attB1r_Ppos-
1_R 
GGGGACTGCTTTTTTGTACAAACTTGTTTTGAATCTAGAA
AAATAAATTTACAAACTG 
18 
attB4_Psip-
1_F 
GGGGACAACTTTGTATAGAAAAGTTGATTTTGCGTGCAA
TGCATTT 
19 
attB1r_Psip-
1_R 
GGGGACTGCTTTTTTGTACAAACTTGTAGTTGAGTGAAT
AGGGTTAAGAATGAGG 
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Table 3.2 – Worm strains generated in Chapter 3. 
 
 
Strain 
Name 
Strain Background Injected transgenic construct 
MMA17 
EG6699 [ttTi5605 II; unc-119(ed3) III; 
oxEx1578] 
CFJ150 alg-1p::gfp::alg-1::unc-54 3′UTR 
MMA18 
EG6699 [ttTi5605 II; unc-119(ed3) III; 
oxEx1578] 
CFJ150 ges-1p::gfp::alg-1::unc-54 3′UTR 
MMA19 
EG6699 [ttTi5605 II; unc-119(ed3) III; 
oxEx1578] 
CFJ150 myo-3p::gfp::alg-1::unc-54 3′UTR 
MMA20 
RF54 [alg-1(gk214) X] + MMA17 
[CFJ150 alg-1p::gfp::alg-1::unc-54 
3′UTR II] 
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Chapter 4 
 
A potential novel role for miRNA in regulating tissue-
specific alternative splicing 
 
Publication note 
 
The research reported in this chapter has been submitted for publication in 
Genetics. Kasuen Kotagama, Anna L Schorr, Hannah S Steber, and Marco Mangone. All 
co-authors have granted permission for this work to be included in this dissertation. 
 
Overview 
 
Splicing is a critical mechanism which determines the exons available for 
translation and is catalyzed by a large RNA protein complex known as the spliceosome. 
In higher eukaryotes, the major splicing complex consists of the U1, U2, and U4/U6 
small nuclear ribonucleoproteins (snRNPs), which contain small nuclear RNAs 
(snRNAs) to identify splice sites in mRNAs [222]. The functional spliceosome in cells 
can include upwards of 80 proteins that interact with each other [223]. One category of 
RBPs that associate with the spliceosome are known as splicing factors, which enhance 
or decrease the usage of specific splice sites and contribute to a mechanism known as 
alternative splicing (Figure 4.1) [222]. Alternative splicing leads to the production of 
different protein isoforms using single mRNA precursors, fine-tune regulatory networks 
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and contribute to the acquisition of tissue identity and function. Alternative splicing 
occurs in >90% of multi-exon genes in humans [224, 225], and is one of the mechanisms 
by which the human genome with only ~20k genes can produce ~30k proteins [226]. This 
mechanism is required to ensure that each tissue possesses the correct gene expression 
pattern needed to thrive [227] and many aberrant alternative splicing events are linked to 
diseases [228, 229].  
 
 
Figure 4.1 – Alternative splicing can be directed by splicing factors. Splicing 
factors bind to sequence elements in the mRNA transcripts (ESS – Exonic splice 
silencer, ISS – Intronic splice silencer, ISE – Intronic splice enhancer, Exonic splice 
enhancer) and promote or repress splice site usage leading to exon inclusion or exon 
skipping.  
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Tissue-specific alternative splicing has been observed in many multicellular 
organisms [227, 230-234]. However, many splicing factors that produce alternative 
splicing are transcribed with promoters that are expressed ubiquitously across tissues. It 
is believed that alternative splicing is regulated in a combinatorial manner by multiple 
interactions between splicing factors [235-237]. Splicing factors act by bind specific cis-
acting elements located within exon/intron junctions in a combinatorial manner, 
promoting or inhibiting splicing. One class of splicing factor, Serine Arginine (SR) 
proteins recognize exon splicing enhancers (ESEs) and are important in promoting 
constitutive and alternative pre-mRNA splicing. While heterogeneous nuclear 
ribonucleoproteins (hnRNPs) are a large class of nuclear RBPs that bind exon splicing 
silencers (ESSs) and usually promote exon retention [238]. The relative expression levels 
of members from these two classes of splicing factors vary between tissues, and this 
imbalance is believed to promote the outcome of tissue-specific alternative splicing 
events [239, 240]. 
A study performed by Cáceres et al. in 1994 showed that the regulation of tissue-
specific alternative splicing occurs through the dosage of splicing factors [239]. In this 
particular study, the overexpression of a single splicing factor, SF1, forced the expression 
of a muscle-specific isoform of tropomyosin in mouse embryonic fibroblasts. The study 
also provided evidence that the relative expression level of a second splicing factor 
hnRNP A1 had an antagonistic effect on splice site selection. These results suggest that 
the corresponding dosage of splicing factors can have an impact on tissue-specific 
alternative splicing. A study by Boutz et.al in 2007, showed that the expression of an 
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alternative splicing factor, polypyrimidine tract-binding protein (PTBP1), can be 
regulated by the miRNA miR-133 during muscle development [241]. When taken in 
context with the results from Cáceres et al. in 1994, which showed that alternative 
splicing is regulated in a dosage dependent manner [239], we hypothesized that miRNAs 
regulate the dosage of splicing factors to influence tissue-specific alternative splicing.  
In fact, an analysis of our tissue-specific miRNA target data sets from the 
intestine and body muscle reveled a large number of RBPs targeted in both tissues, with a 
specific enrichment of splicing factors targeted in the intestine. We validated the 
regulation of candidate splicing factors, hrp-2, asd-2 and smu-2, and find that they are 
indeed regulated through their 3’UTRs in the intestine. We tested the implications of 
miRNA targeting to the alternative splicing patterns of genes regulated by asd-2 and hrp-
2 (unc-60, lin-10, unc-52 and ret-1), and find that the alternative splicing of all four genes 
are impacted by miRNAs. To explore the extent to which miRNAs contribute to 
alternative splicing, we used publicly available transcriptome data from worm strains 
deficient in the miRNA pathway and found genome wide dysregulation of splicing in the 
absence of miRNAs. The results presented in this chapter suggest a potential novel role 
for miRNAs in mRNA biogenesis, where regulation of splicing factors by miRNAs 
produces tissue-specific alternative splicing.  
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Results 
 
Intestine and body muscle miRNAs target RNA binding proteins  
Upon further analysis, we observed an unexpected enrichment of genes 
containing RNA binding domains in both the intestine and body muscle datasets. 
RNA binding proteins are known to play an important role in producing tissue-
specific gene regulation by controlling gene expression at both the co- and post-
transcriptional levels [242], and out of the ~887 RNA binding proteins (RBPs) 
defined in C. elegans [242], we identified almost half as targets of miRNAs 
across both tissues (45%).  
 
 
Figure 4.2 - Proportion of RBPs targeted by miRNAs in each tissue. There is an 
enrichment of RBPs targeted in the intestine (green 64%) and the body muscle (blue 
54%). ‘TFs’ represents genes annotated as transcription factors while ‘Other’ 
represents protein-coding genes that are not RBPs. 
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We found that out of the 599 known RBPs present in the intestine 
transcriptome [56, 191], 380 (64%) were present in our intestine dataset as targets 
of miRNAs (Figure 4.2). This is a notable enrichment when compared to 
transcription factors and non-RBP genes found in these tissues by Blazie et al. 
2017 [56], of which only a fraction were identified in our study as miRNA targets 
(Figure 4.2) 
A similar trend is also present in the body muscle, with 170 (54%) of RBPs 
identified as miRNA targets (Figure 4.2). Importantly, the largest pool of targeted RBPs 
in both tissues was composed of general factors (GF), such as translation factors, tRNA 
interacting proteins, ribosomal proteins, and ribonucleases (Figure 4.3), suggesting 
extensive miRNA regulatory networks are in place in this tissue. 
 
 
 
Figure 4.3 - Subtypes of RBPs targeted by miRNAs in the intestine and 
body muscle. GF - General Factors, including translation factors, tRNA 
proteins, ribosomal proteins, and ribonucleases; ZF - Zinc finger; RRM - RNA 
recognition motif; HEL - RNA Helicase; PAZ - PIWI PAZ, PIWI, Argonautes.  
The majority of the targeted RBPs are general and zinc finger-containing 
factors. 
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miRNAs target RNA splicing factors 
Further analysis of the RNA binding proteins targeted in each tissue 
revealed that one of the most abundant classes of RBPs detected in our ALG-1 
pull-down in the intestine and body muscle datasets were RNA splicing factors 
(Figure 4.4). The C. elegans transcriptome contains at least 78 known RNA 
splicing factors involved in both constitutive and alternative splicing [242]. 64 
RNA splicing factors (82%) have been previously assigned by our group in the 
intestine [56, 191] and presumably are responsible for tissue-specific RNA 
splicing. 31 RNA splicing factors (40%) were also previously assigned by our 
group to the body muscle tissue [56, 191].  
 
 
Figure 4.4 - RNA Splicing factors identified as miRNA targets in the intestine and 
body muscle tissues. Intestine – green. Body muscle – blue. More than half of the RNA 
splicing factors examined are targeted by miRNAs in the intestine as compared to body 
muscle. 
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Our tissue-specific ALG-1 pull-down identified 37 RNA splicing factors 
as miRNA targets in the intestine (~47%) (Figure 4.4), and 34 of these were also 
previously identified by our group as being expressed in this tissue [56, 191]. In 
contrast, we have detected only nine RNA splicing factors targeted by miRNAs in 
our body muscle tissue ALG-1 pull-down, five of which previously assigned by 
our group in the body muscle transcriptome [56, 191] (Figure 4.4).  
The difference in RNA splicing factors targeted by miRNA in these two 
tissues is significant as with the intestine contains three orders of magnitude more 
miRNA targeted RNA splicing factors than the body muscle. Of note, many 
different sub-types of RNA splicing factors identified in this study have human 
homologs, such as well-known snRNPs, hnRNPs and SR proteins (Figure 4.4).  
 
Expression of the RNA splicing factors asd-2, hrp-2 and smu-2 is modulated through 
their 3’UTRs 
In order to validate that RNA splicing factors found in our ALG-1 pull-down IPs 
are targeted by miRNAs in the intestine, we used the pAPAreg dual fluorochrome vector 
we developed in a past study [56]  (Figure 4.5). This vector uses a single promoter to 
drive the transcription of a polycistronic pre-mRNA where the coding sequence of the 
mCherry fluorochrome is separated from the coding sequence of GFP by a SL2 trans-
splicing element (SE) [56]. The test 3’UTR is cloned downstream of the GFP gene. Since 
the mCherry transcript is trans-spliced, it reports transcription activation. The GFP gene 
instead reports translational activity; since its expression is dictated by the downstream 
tested 3’UTR.  If a given miRNA targets the test 3’UTR, the GFP intensity decreases 
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when compared with an untargeted 3’UTRs (ges-1). By comparing the ratio of the 
mCherry (indicating transcription) to the GFP (indicating translation) fluorochromes, we 
are able to define the occurrence of post-transcriptional silencing triggered by the tested 
3’UTR (Figure 4.5) [56].   
We selected three representative RNA splicing factors identified in our 
study in the intestine (asd-2, hrp-2 and smu-2) and prepared transgenic strains to 
validate their expression and regulation (Figure 4.6). We used the ges-1 3ʹUTR as 
a negative control for miRNA targeting, as it is strongly transcribed and translated 
in the intestine, with no predicted miRNA binding sites (PicTar), and poorly 
conserved seed regions (TargetScan), suggesting minimal post-transcriptional 
gene regulation [243, 244]. ges-1 was not significantly abundant in our intestine 
ALG-1 pull-down. The presence of the ges-1 3ʹUTR in the pAPAreg vector led to 
the expression of both mCherry and GFP fluorochromes, indicating robust 
transcription and translation of the construct as expected (Figure 4.6). 
We then cloned asd-2, hrp-2 and smu-2 3ʹUTRs downstream of the GFP 
fluorochrome in our pAPAreg vector, prepared transgenic worms expressing these 
 
Figure 4.5 - Diagram of the construct used in these experiments (pAPAreg). An 
intestine-specific promoter drives the expression of a bi-cistronic dual fluorochrome 
vector in the intestine. The mCherry fluorochrome reports transcription activity of the 
construct, while the GFP reports post-transcriptional activity through the test 3’UTR 
cloned downstream of the GFP reporter sequence. If the test 3’UTR is targeted by 
repressive regulatory factors, such as miRNAs, the GFP fluorochrome lowers in its 
expression. SE: trans-splicing element extracted from the intergenic region located 
between the genes gpd-2 and gpd-3. 
 
mcherry 3′UTRSEIntestine promoter gfp
Transcriptional 
reporter
Translational 
reporter
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constructs, and studied the fluctuation of the expression level of the GFP fluorochrome in 
these transgenic strains. All three 3ʹUTRs were able to significantly lower GFP 
expression when compared to the control strain with the ges-1 3`UTR, with ~40% 
repression, while the mCherry signal was similar in all strains (Figure 4.6). These results 
suggest that these three RNA binding proteins contain regulatory binding sites within 
their 3ʹUTRs potentially able to repress their expression.  
 
MiRNAs target intestine RNA splicing factors promoting tissue-specific alternative 
splicing 
We then tested changes to tissue-specific alternative splicing in the intestine 
caused by the STAR protein family member asd-2, which regulates the alternative 
splicing pattern of the gene unc-60. unc-60 is expressed as two alternatively spliced 
isoforms in a tissue-specific manner [245] (Figure 4.7); unc-60a is expressed 
predominantly in the body muscle while unc-60b is expressed in many other tissues 
including the intestine [245]. 
We first tested the unc-60 RNA isoform ratio in wt N2 worms. We 
extracted total RNA from N2 worms in triplicate and performed RT-PCR 
experiments using primers flanking the two unc-60 isoforms (Figure 4.7). As 
expected, we found that the unc-60a longer isoform was more abundantly 
expressed in wt worms (62%) (Figure 4.8 and 4.9).  
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Figure 4.6 - Representative images of C. elegans strains generated with pAPAreg 
constructs expressing one of the following 3’UTRs: ges-1, asd-2, hrp-2 or smu-2 
downstream of the GFP fluorochrome. Yellow boxes indicate magnified regions. 
White dotted lines indicate the intestine. C) The bar graphs show the quantified and 
normalized mean fluorescence ratio between the GFP and the mCherry fluorochromes. 
The mean fluorescence ratio is calculated from 10 worms per strain. Student t-test 
*p<0.05. We observed ~40% reduction in normalized GFP intensity modulated by asd-
2, hrp-2, and smu-2 3’UTRs. 
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Figure 4.7 - Schematic of the genomic locus of unc-60. This gene is expressed as a 
longer unc-60a isoform, and a shorter unc-60b isoform. Arrows mark the binding sites 
of the primers used to detect the two isoforms. 
Gene: unc-60
Splicing factor: asd-2
1 2a 3a 4a 5a 2b 3b 4b 5b
 
 
Figure 4.8 - RT-PCR performed from total RNA extracted from biological 
replicates in triplicate and visualized in 1% agarose gel. 1) N2: wt worms. 2) alg-1 
k/o: RF54[alg-1(gk214) X], 3) alg-2 k/o: WM53[alg-2(ok304) II], 4) asd-2 RNAi: N2 
worms subjected to asd-2 RNAi, 5) Over expression of asd-2 3’UTR in the intestine. 
 
1 2a 3a 4a 5a
1 2b 3b 4b 5b
365bp
581bp
1k
N2 alg-1 k/o alg-2 k/o asd-2 RNAi asd-2 3′UTR
 
 
Figure 4.9 – The splicing pattern of unc-60 is modulated by miRNA activity in 
the intestine. The pie charts below each gel show quantification of each of the 
occurrence of the two isoforms. The percentage below the pie chart is the increase in 
unc-60 isoform b abundance when compared to N2(wt). The bar chart shows the 
change in isoform ratio between strains. The y-axis shows the abundance ratio (shorter 
isoform/longer isoform) of the two alternatively spliced isoforms examined. Exon 
skipping increases in alg-1 and alg-2 k/o strains, and in asd-2 3’UTR overexpression 
strains. Error bars indicate standard error of the mean. Student t-test *p<0.05 
**p<0.01. 
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We then investigated if the miRNA pathway has a role in regulating these 
splicing events, by testing changes in unc-60 isoform abundance in the alg-1 and 
alg-2 knockout strains (RF54 (alg-1(gk214) X) and WM53(alg-2(ok304) II). 
These strains are deficient in miRNA-based gene regulation. We found that loss 
of these miRNA effectors leads to a 10-20% shift in the expression of the two 
unc-60 isoforms (Figure 4.5 and 4.9), indicating the importance of the miRNA 
pathway in regulating alternative splicing of this gene.  
We then used a genetic approach to test the alternative splicing of this 
gene in the context of miRNA regulation. We reasoned that if ALG-1 targets the 
asd-2 3’UTR in the intestine lowering the expression of asd-2, which in turn 
causes unc-60 alternative splicing pattern, we should be able to interfere with this 
 
Figure 4.10 - Brood size assay to determine the efficiency of RNAi targeting 
hrp-2 and asd-2. RNAi performed against the gene par-2 (positive control) 
produced almost no hatched larvae as expected. A decrease in brood size was 
observed when RNAi was performed for the splicing factors hrp-2 and asd-2 
indicating the knockdown of these genes. **p<0.01 n=5 
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mechanism by overexpressing the asd-2 3’UTR in this tissue and in turn test the 
role of the miRNA pathway in this process.  
As expected, the overexpression of the asd-2 3ʹUTR in the intestine led to 
changes in the unc-60 alternative splicing pattern, indicating that post-transcriptional 
regulation of asd-2 through its 3ʹUTR is important for the alternative splicing pattern of 
unc-60 in the intestine (Figure 4.8 and 4.9). Conversely, asd-2 RNAi did not induce 
changes in unc-60 alternative splicing pattern (Figure 4.8 and 4.9).  
We validated the efficiency of our RNAi experiments by performing a brood size 
assay, which indicated strong RNAi activity (Figure 4.10). Similar results were observed 
by testing a second splicing factor (hrp-2) known to direct alternative splicing of the 
genes ret-1, lin-10 and unc-52 [246, 247] (Figure 4.11).  
 
Loss of miRNA function lead to dispersed changes in splice junction usage 
Since our data support a role for the miRNA pathway in modulating mRNA biogenesis, 
we were interested in testing the extent of these effects at the transcriptome level. We 
decided to download and mapped splicing junctions in genes from alg-1 and alg-2 
knockout strains previously published by Brown et al., 2017 [177].  These worm strains 
are viable but are severely impaired. We reasoned that if the miRNA pathway contributes 
at some level to mRNA biogenesis, we should be able to see widespread changes in the 
usage of splice junctions in these datasets. To test this hypothesis, we downloaded the 
alg-1 and alg-2 datasets (three replicates for each strain plus wt N2 control), and 
extracted splice junction information.  
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Figure 4.11 - lin-10, unc-52 and ret-1 exon skipping events in the intestine (1) 
Biochemical evidence. Top panels: The lin-10, unc-52 and ret-1 gene models are 
shown to illustrate the alternatively spliced exons (red) and the primer pairs used in 
the RT-PCR experiments to detect intestine specific alternative splicing modulated by 
miRNAs. Bottom Panels: Agarose gels visualizing RT-PCRs performed in triplicate 
on independent RNA extractions to test changes of alternative splicing of individual 
genes. *p < 0.05; **p <0 .01 
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We first tested if the effects we observed in unc-60 with our biochemical and genetic 
approaches (Figure 4.8 and 4.9) could also be detected in these datasets. In the case of 
unc-60, there is a 6-10% change in splice junction usage between isoforms consistently in 
all re-annotated replicates, in both alg-1 and alg-2 knockout strains (Figure 4.12). This 
result is in line with our analysis in Figure 4.8 and 4.9. A similar and more striking 
aberrant splice junction usage is observed in the case of lin-10, and unc-52, and with a 
less pronounced effect in ret-1 (Figure 4.13). These results are also in agreement with our 
study in Figure 4.11.  
We then expanded this analysis to all splicing junctions we were able to map 
using these transcriptomes. From a total of 30,115 high quality known splice junctions 
 
Figure 4.12 (next page) - Comparison of the splice junction usage in unc-60 as 
observed in transcriptome data for alg-1 and alg-2 knockout strains (BROWN et 
al. 2017). The numbers above each slice junction indicates the number of reads 
mapped to that splice junction. The total reads for each isoform are indicated next to 
the gene model. The isoform ratios indicated next to the gene models are calculated by 
dividing the total reads for each isoform. There is a ~6-10% increase in the expression 
of the shorter unc-60b isoform in the miRNA deficient strains. Blue: reads 
corresponding to unc-60a. Orange: reads corresponding to unc-60b. 
Isoform 
ratio b/a 
+6%
+10%
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0.371
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present in all three datasets, we identified ~3,946 of them in ~2,915 protein-coding genes 
that were affected by more than 2-fold change in usage in both alg-1 and alg-2 knockout 
datasets (~13.2% of the total mapped splice junctions) (Figure 4.13). In addition, we 
detect several cases of exon inclusion, skipping and aberrant splicing events that occur 
exclusively in the alg-1 and/or alg-2 mutant strains (Figure 4.14). 
 
Figure 4.13 - lin-10, unc-52 and ret-1 exon skipping events in the intestine 
(2) Sashimi plots generated by re-analyzing RNA-seq data from Brown 
et.al 2017. Replicates for each strain were combined and analyzed with the 
TopHat bioinformatic package. The plots illustrate the number of reads 
mapped for each splice junction. Top and middle panels: The splicing events 
for lin-10 and unc-52 showed an increase of exon skipping occurring in both 
miRNA deficient strains. Lower panel: ret-1 exon 5 skipping increases 
slightly in alg-2 but shows increased exon inclusion in alg-1 knockout 
worms. Yellow boxes highlight alternatively spliced exons analyzed in this 
figure S: total reads for the short isoform; L: total reads for the long isoform. 
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Figure 4.14 - Genome-wide changes in splice junction usage in C. elegans strains 
deficient in the miRNA pathway. Analysis of splice junction (SJ) usage in miRNA 
deficient strains (alg-1(gk214) or alg-2(ok304)) re-annotated from Brown et al. 2017 
(BROWN et al. 2017). The graphs illustrate the changes in splice junction abundance 
for different types of splicing events. The x-axis represents the fold-change of the 
normalized number of reads for each splice junction, comparing the alg-1(gk214) 
strain to wt, while the y-axis represents the fold change obtained when comparing alg-
2(ok304) to wt. Splice junctions with more than 2-fold enrichment in both strains are 
highlighted in blue, while splice junctions with 2-fold depletion in both strains are 
highlighted in red. The number of genes (G) with enriched or depleted splice junctions 
are indicated next to the graphs. There is a 2-fold change in ~13% of all the splicing 
events mapped in the knockout strains, affecting 3,301 genes when compared to the N2 
wt control. 
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Discussion 
 
RBPs are enriched in the tissue-specific miRNA target datasets in both the intestine and 
body muscle 
We found that miRNAs target RBPs in a tissue-specific manner, including 
several mRNA splicing factors such as hnRNPs and SR proteins (Figure 4.4). 
64% of the RBPs expressed in the intestine were found in our intestinal ALG-1 
pull-down, while 54% of the muscle RBPs were in our muscle ALG-1 pull-down. 
This result was unexpected given the small number of RNA binding proteins 
 
 # of novel splice junction 
 exon 
aberrant 
 inclusion skipping 
alg-1 1,622 1,840 409 
alg-2 1,897 1,231 456 
both 2,526 1,766 153 
either 6,045 4,837 1,018 
Figure 4.15 - The table summarizes the number of novel splicing events seen in 
alg-1 and alg-2 datasets. These are splicing events not observed in the N2 wt control, 
and indicate an increase in novel and aberrant splicing events in miRNA deficient 
strains.  
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previously identified in the C. elegans genome (n = 887) [242], which amounted 
to only 4% of the total C. elegans protein-coding genes. However, previous 
studies have hinted at a strong regulatory network between miRNAs and RBPs, as 
the 3’UTRs of RBPs were found to contain on average more predicted miRNA 
binding sites than other gene classes [242].  
RNA binding domain-containing proteins are involved in many biological 
processes, and their role is not limited to RNA biogenesis [242]. RBPs can bind 
single or double strand RNAs, and associate with proteins forming 
ribonucleoprotein complexes (RNPs). Longevity, fat metabolism, and 
development are all processes controlled by RNPs [182, 248, 249], and in the 
context of miRNA regulation, the ability of miRNAs to control RBPs abundance 
and function allows for increased control of fundamental cellular core processes. 
234 RBPs uniquely detected as miRNA targets in the intestine, while 147 RBPs 
are shared between both datasets. 
 
RNA Splicing factors are regulated by miRNAs in a tissue-specific manner and 
influence alternative splicing  
Within this intestinal dataset, we mapped a surprising number of RBPs 
involved in RNA splicing (Figure 4.4). We performed a literature search for 
known RNA splicing factors in C. elegans; out of the 72 total protein identified, 
37 of them were enriched in our intestine ALG-1 pull-down.  In contrast, we do 
  104 
not observe this level of complexity in the body muscle, with only 9 RNA 
splicing factors identified in this dataset (Figure 4.4).  
asd-2 and smu-2 are well-known RNA splicing factors that induce exon 
retention in a dosage-dependent manner [245, 250], while hrp-2 abundance leads 
to exon skipping [246]. Here we show that all three RNA splicing factors possess 
regulatory targets within their 3’UTRs (Figure 4.5 and 4.6) that amount to ~40% 
silencing activity in the intestine (Figure 4.5). Although we do not know which 
miRNAs target the asd-2 and hrp-2 3’UTRs, in Figures 4.7 – 4.9 and Figure 4.11 
we show that the miRNA pathway influences splice junction usage by regulating 
these genes. The depletion of miRNAs which target these RNA splicing factors 
by using sponge approaches led to defects in the alternative splicing pattern of 
downstream genes regulated by asd-2 and hrp-2. 
Interestingly, the miRNAs predicted to target most splicing factors were 
not found highly expressed in this study. miR-85 and miR-355, the most abundant 
and tissue-restricted miRNAs identified, are only predicted to target less than 10% 
of all the RBPs found.  This suggests that since miRNAs are highly reactive, the 
abundance of those involved in regulating RNA alternative splicing may be 
tightly regulated in tissues, to make sure splicing events are properly executed. 
 Our genome-wide splice junction mapping effort in miRNA deficient 
strains shows similar trends of aberrant splicing of unc-60, unc-52, lin-10 and ret-
1 (Figure 4.12 and 4.13) and display an overall disruption of splicing events 
(~13.2% of all splice junctions mapped) (Figure 4.14 and 4.15). Most of these 
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defects are in known donor-acceptor splicing events, perhaps because RNA 
surveillance mechanisms may hide more severe disruptions. 
Unfortunately, our in vivo approach does not reach the resolution needed 
to conclusively pinpoint the extent of the miRNA pathway in this process. To 
perform in vivo experiments, we used total RNA extracted from transgenic worms 
and studied the change in exon abundance occurring in a single tissue within a 
whole animal, which prevented us from reaching the same resolution obtainable 
with in vitro splicing experiments and mini-genes. In addition, the effects we 
observe are ameliorated by the presence of at least one functional Argonaute 
protein, which can compensate for the loss of the other. Knockout of the entire 
miRNA pathway is lethal in C. elegans, and while aberrant splicing may play a 
role in producing this phenotype, these activities are challenging to detect in vivo.  
Taken together, our results support a role for miRNAs in regulating 
alternative splicing in the intestine, where their presence in a tissue-specific 
manner may lead to alteration of the dosage balance of RNA splicing factor, 
leading to tissue-specific alternative splicing. MiRNAs are known to alter gene 
expression dosage, rather than induce a complete loss of protein function [11, 15]. 
On the other hand, many RNA splicing factors involved with constitutive and 
alternative splicing are ubiquitously expressed [251] but are somehow able to 
induce tissue-specific alternative splicing in a dosage-dependent manner. In this 
context, it is feasible that miRNAs may alter the dosage of RNA splicing factors, 
leading to tissue-specific alternative splicing.  
  106 
Experimental 
 
Cloning of expression constructs and preparation of transgenic strains 
The 3ʹUTRs of the genes in this study were cloned by anchoring the Gateway-
compatible primers at the translation STOP codon of each gene, to the longest annotated 
3`UTR (Primers 1-6 Table 4). We have included 50 base pairs downstream of the 
annotated PAS site to include 3ʹend processing elements. The PCR products were 
analyzed using gel electrophoresis analysis and used to perform Gateway BP Clonase 
reactions (Invitrogen, cat. 11789020) into pDONR P2RP3 as per the manufacturer’s 
protocol. The unc-54 3ʹUTR used in this study was previously described in Blazie et al., 
2017. The constructs injected were assembled by performing Gateway LR reactions 
(Invitrogen) with each promoter, reporter, and 3ʹUTR construct per the manufacturer’s 
protocol into the MosSCI compatible destination vector CFJ150. We then microinjected 
each reporter construct (100ng/μl) with CFJ601 (100ng/μl) into MosSCI compatible C. 
elegans strains using standard microinjection techniques [217]. 
 
Fluorescent imaging and analysis of nematodes 
Confocal images used in Figure 4.6 were acquired in the Biodesign 
Imaging Core, Division of the Arizona State University Bioimaging Facility. 
Transgenic strains were grown at room temperature on NGM plates seeded with 
OP50-1. The mixed stage worms were washed twice with M9 and resuspended in 
1mM of levamisole before imaging using a Nikon C1 Ti-E microscope with 488 
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nm and 561 nm lasers, 0.75 numerical aperture, 90 μM pinhole microscope with a 
40x magnification objective lens. We acquired 10 images for each transgenic 
strain (total of 40 images) using the same microscope settings. The fluorescence 
of GFP and mCherry fluorochromes from the acquired images were individually 
quantified using the integrated density (ID) function of the ImageJ software [252]. 
Fluorescence ratios were then calculated for each worm (n=10, total 40 images) 
by dividing the ID for GFP by the ID for mCherry. The finalized result for each 
strain is the averaged fluorescence ratio calculated across all 10 imaged worms. 
We performed a two-tailed student t-test to compare the mean fluorescence ratios 
for each strain with a p-value cut off <0.05 to establish the presence of post-
transcriptional gene regulation. 
 
Re-annotation of alg-1 and alg-2 knockout transcriptome datasets and splice junction 
identification 
We downloaded from the GEO database the following transcriptome datasets 
published by Brown et al., 2017 [177]: Project number GSE98935, Wild type Rep 1-3 
(GSM2628055, GSM2628056, GSM2628057); alg-1(gk214) Rep 1-3 (GSM2628061, 
GSM2628062, GSM2628063); alg-2(ok304) Rep 1-3 (GSM2628064, GSM2628065, 
GSM2628066). We used in-house Perl scripts to prepare the reads for mapping, and then 
these reads as input to the TopHat algorithm [253] to map splice junctions in all nine 
datasets independently. The TopHat algorithm mapped between 30-56M reads to splice 
junctions in each sample. wt_rep1;  43,721,355 mapped reads (64% of total input reads), 
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wt_rep2; 44,440,441 (64%), wt_rep3; 37,248,408(62.7%), alg-1_rep1; 30,808,645 
(62.3%), alg-1_rep2; 35,914,514 (63.2%), alg-1_rep3; 43,721,355(63.9%),  alg-2_rep1; 
54,471,761(63.2%), alg-2_rep2; 56,000,173 (66.8%), alg-2_rep3; 46,638,369 (63.9%). 
We then combined the mapped reads obtained in the three replicates for each strain and 
used the open source software regtools (Griffith Lab, McDonnell Genome Institute) to 
annotate these splice junctions using the following command ‘regtools junctions annotate 
junctions.bed WS250.fa WS250.gtf’. The software produced ~41.8k splice junctions 
supported by at least 10 reads for the combined N2 wt dataset, ~42.3k splice junctions for 
the alg-1 dataset and 46.3k for the alg-2 dataset. We analyzed the three resulting 
cumulative datasets normalized by dividing each score by the total number of mapped 
reads within each sample. This approach produced 36.7k high-quality splice junction for 
the combine N2 wt dataset, ~37k for the alg-1 combined dataset and ~38k for the 
combined alg-2 dataset. The analysis in Figures 4.14 and 4.15 were performed using 
splice junctions that are present in all three datasets (30,115 total). To calculate the fold-
change for each splice junction, we divided the normalized scores of each splice junction 
in the alg-1 and alg-2 combined datasets by the corresponding scores in the wild type 
combined dataset. The fold change of each splice junction was then plotted on a log2 
scale shown in Figure 4.14. 
 
RNAi experiments 
The RNAi experiments shown in Figure 4.8 and Figure 4.11 were performed as 
follows. N2 worms were synchronized by bleaching and starving overnight in M9 buffer 
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until they reached the L1/dauer stage and then transferred to agar plates containing OP50-
1 bacteria, HT115 bacteria with pL4440 hrp-2 RNAi or pL4440 asd-2 RNAi [254]. We 
used par-2 RNAi as a positive control for the experiments, which results in 100% 
embryonic lethality. To measure the brood size, individual synchronized young adult 
worms were left overnight (16 hours) to lay eggs. Hatched larvae were counted 24 hours 
later. Total RNA was extracted from N2 worms treated with either hrp-2 or asd-2 RNAi 
at the adult stage in triplicates.  
 
RNA extraction for detection of intestine-specific splicing variants 
We extracted total RNA using the Direct-zol™ RNA MiniPrep Plus kit (Zymo 
Research, cat ZR2070) from (1) N2 wt worms, (2) RF54 (alg-1(gk214) X) strain, (3) 
WM53 (alg-2(ok304) II) strain, (4) N2 strain subjected to RNAi as previously 
described[255] for asd-2 and hrp-2, and (5) transgenic worms overexpressing the asd-2 
3’UTR or the hrp-2 3’UTR under control of an intestinal promoter (ges-
1p::pAPAreg::3’UTR ). Each strain was synchronized by growing in M9 media to 
L1/dauer stage then transferred to plates containing HT115. We extracted RNA 48 hours 
later from adult worms in triplicate for each condition. 
 
cDNA preparation, image acquisition and splicing isoform analysis 
cDNA was synthesized from each RNA sample using SuperScript III RT (Life 
Technologies, cat 18080093) according to the manufacturer’s protocol. Briefly, 200ng of 
each RNA sample was incubated with 1 µL of 50mM poly dT anchor, 1 µL of 10mM 
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dNTP mix and brought to a total volume of 14 µL with nuclease-free H2O and incubated 
for 5 minutes at 60°C then iced for 1 minute. 4 µL of 5x first strand buffer, 1 µL of 0.1M 
DTT and 1 µL (200 units) of SuperScript III reverse transcriptase were added to each 
sample and incubated at 50°C for 60 minutes then heat inactivated at 70°C for 15 
minutes. 200ng of cDNA from each sample was used in PCRs consisting of 34 cycles 
using HiFi Taq Polymerase (Invitrogen, cat 11304011) according to manufacturer 
protocols. Primers used to test alternative splicing of unc-60, unc-52, lin-10, and ret-1 
were designed to flank the alternatively spliced exons and were adapted from previous 
studies (Table 4.1 primers 7-15) [245-247]. We then acquired images of the PCR 
amplicons (5 µL) separated by agarose gel electrophoresis. We used the integrated 
density function of ImageJ [252], by defining equally sized regions of interest around 
each band in the images and compared the integrated density values by normalizing the 
smaller bands to the larger bands. The resulting isoform ratios are displayed in Figures 
4.9 and 4.11. Each strain was quantified in triplicate and subjected to a two-tailed student 
t-test. Statistical significance was assigned for p-values <0.05.  
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 Table 4.1 - Primers used in Chapter 4
Primer 
# 
Primer Name Primer sequence 
1 atB2r_asd-2_F 
GGGGACAGCTTTCTTGTACAAAGTGGAG 
TAACCAACCAACACCACCAAC 
2 attB3_asd-2_R 
GGGGACAACTTTGTATAATAAAGTTG 
ATTGAATTCATAAAACTGTTTTCTTGC 
3 attB2r_hrp-2_F 
GGGGACAGCTTTCTTGTACAAAGTGGAG 
TAAATTGCACCCCCGGCAGA 
4 attB3_hrp-2_R 
GGGGACAACTTTGTATAATAAAGTTG 
CAAATTTGGGCAAACTTCCG 
5 attB2r_smu-2_F 
GGGGACAGCTTTCTTGTACAAAGTGGAG 
TGATTTTTTTAATGATTTTTATGAATTC 
6 attB3_smu-2_R 
GGGGACAACTTTGTATAATAAAGTTG 
AATAATTCGATTTTTATCATTTTCAG 
7 lin-10_exon5_F AAGAATCAGCGGGAGGAGAG 
8 lin-10_exon8_R GATGTGGTTGCATCATCTGG 
9 ret-1_exon4_F CATCCGCTGAAGGATCCATAG 
10 ret-1_exon6_R GAGCTTCCTCAGCAATCGGAG 
11 unc-52_exon16_F CGGACATCCAAGTGTTCAGC 
12 unc-52_exon19_R AACTGATGTCGCTCTCCTGG 
13 unc-60_exon1_F GAAACTCAACTTGATTCTATTTCCCC 
14 unc-60_exon5A_R CGACGACGACTTCGGAAGAGAC 
15 unc-60_exon5B_R GACTGGGGCGTTGTCTGGGC 
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Chapter 5 
Conclusion 
MicroRNA targetting principles uncovered using the h3’UTRome 
The h3’UTRome (Chapter 2) is the first publicly available compendium of human 
3’UTRs, and has enabled the study of human miRNA targets at the genomic level. 
Identifying miRNA targets at this scale has enabled us to observe targeting principles that 
were not apparent in low-throughput studies. Our results indicate that miRNAs target 
gene pathways by regulating multiple genes in the same pathway, as seen in the case of 
let-7c targeting multiple members of the RAS pathway. Expanding on these initial 
observations we have used the h3’UTRome and the 3’LIFE assay, to further identify the 
targets of let-7c and miR-10b [11]. We found further evidence that these miRNAs 
regulate gene pathways at multiple points, eluding to a general mechanism by which 
miRNAs act in cells [11]. This general targeting principle presents a possible explanation 
as to how miRNAs, that rarely silence genes entirely, are able to have significant effects 
on phenotypes.  
Using the h3’UTRome, we identified regions of miRNAs outside the seed that 
impact target identification [11]. In this study we screened the h3’UTRome against 
multiple members of the miR-10 family, which shares the same seed sequence but has 
differences at the 3’end of the miRNA. We found that these miRNA family members, 
that were believed to be functionally redundant, share many of the same targets but are 
able to target unique genes based on differences outside the seed. These observations 
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were made possible by studying miRNA targets at the genomic level using the 
h3’UTRome. Currently, the h3’UTRome captures only ~1.5% of the annotated human 
3’UTRs, which while useful, does not allow us to fully identify all the targets of any 
miRNA. Expanding this library would allow us to better appreciate the contributions of 
miRNAs to global gene regulation. 
 
MicroRNAs contribute to tissue-specific gene expression 
Previous studies have identified specific cases where miRNAs are able to regulate 
gene expression in a tissue-specific manner, however the targets of miRNAs had not been 
systematically studied at the tissue-specific level. To study the tissue-specific roles of 
miRNAs, we optimized a crosslinking and immunoprecipitation-based approach to 
isolate and sequence miRNA targets from the intestine and body muscle of C. elegans 
(Chapter 3).  
We found that at the tissue-specific level, miRNAs target gene pathways, and that 
each pathway was targeted at multiple points (Figure 5.1). The pathways regulated by 
miRNAs are important for tissue-specific function, suggesting that miRNAs fine tune 
gene expression to maintain tissue homeostasis. Many RBPs are targeted by miRNAs in a 
tissue-specific manner, and within this group of RBPs we found an enrichment of 
splicing factors targeted by miRNAs. Our data indicates a novel tissue-specific role for 
miRNAs in regulating the biogenesis of mRNA and contributing to alternative splicing 
by adjusting the dosage of splicing factors (Figure 5.2).   
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Figure 5.1 – The tissue-specific targets of miRNAs correspond to the known 
functions of each tissue. The intestine in the worm is responsible for fertility in 
addition to its role in metabolism, while the predominant function of the body muscle is 
to enable locomotion and these tissue-specific roles are reflected in the miRNA targets. 
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Figure 5.2 - A proposed role for miRNAs in the modulation of tissue-specific 
alternative splicing. The abundance of RNA splicing factors (yellow circles) dictates the 
splicing events in a given tissue A. The presence of a miRNA in Tissue B may lower the 
dosage of splicing factors resulting in tissue-specific alternative splicing. 
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Complex RNA-based regulatory networks 
An elaborate program of gene regulation is required to develop and maintain the 
different cell types in a multicellular organism. Recently, the contributions of RNA to 
these regulatory networks have come to light. MiRNAs impact gene regulation 
throughout expression, from epigenetic control of DNA to post-translational modification 
of proteins (Figure 5.3) [241, 256, 257].  
MiRNAs and their target sites in 3’UTRs are regulated in a tissue-specific 
manner, indicating that miRNAs have the potential to dictate tissue-specific gene 
expression. I hypothesized that miRNAs regulate tissue-specific gene expression. To test 
 
Figure 5.3 – An overview of miRNAs in complex RNA-based regulatory 
networks. MiRNAs directly regulate gene expression post-transcriptionally by 
targeting the 3’UTRs of mRNAs (red bar). APA modulates miRNA targeting by 
producing 3’UTR isoforms (red arrow). Due to their wide array of targets, miRNAs 
are able to impact gene regulation at every point of gene expression. 
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this hypothesis, we developed and utilized tools and techniques to identify miRNA 
targets using human cell lines, and in vivo in the model organism C. elegans. The 
research presented in this thesis provides compelling evidence for tissue-specific roles of 
miRNAs. We find that while miRNAs act at the post-transcriptional level, the effects of 
miRNAs can impact gene expression at multiple points leading to complex RNA-based 
regulatory networks that exist at the tissue-specific level (Figure 5.3).  
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GENES FROM THE H3’UTROME SCREENED USING THE 3’LIFE ASSAY 
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target of 
miR-
221/let-
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miR-
221 
miR-
221 
let-
7c/miR-
221 
miR-221 20299489 Y - - 
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NM_024832 RIN3 - - - - - - Y - - 
NM_001271007 STRA13 - - - - - - - - - 
NM_002467 MYC - - - let-7c - - Y - - 
NM_198256 E2F6 let-7c - let-7c let-7c - - - - - 
NM_001789 CDC25A let-7c let-7c let-7c let-7c let-7c 25909324 - - Y 
           
           
NM_007241 SNF8 - - - - - - - - - 
  
1
4
0
 
NM_004040 RHOB - - - - - - Y - Y 
           
           
NM_001665 RHOG - - - - - - Y - - 
NM_014245 RNF7 let-7c let-7c - let-7c - - - - Y 
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miR-
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miR-
221 
miR-221 miR-221 24607843 - - - 
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NM_001191 BCL2L1 let-7c let-7c let-7c let-7c let-7c 23562878 Y - Y 
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let-
7c/miR-
221 
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4
1
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NM_001143976 WEE1 miR-221 - - miR-221 miR-221 23630541 - Y - 
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NM_001256295 ETS2 miR-221 
miR-
221 
- miR-221 miR-221 21715310 Y Y - 
           
           
NM_004556 NFKBIE - - - - - - - - - 
NM_001211 BUB1B - - - - - - - Y Y 
           
           
NM_001185081 FMR1 miR-221 - 
miR-
221 
miR-221 miR-221 23390134 - Y - 
           
           
NM_000222 KIT miR-221 - 
miR-
221 
miR-221 miR-221 21119596 Y Y Y 
           
           
NM_005228 EGFR - - - - - - Y - - 
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NM_002915 RFC3 - - - - - - - - - 
NM_021795 ELK4 - - let-7c - - - - - - 
NM_006343 MERTK - - - - - - - Y Y 
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NM_001260 CDK8 - - - miR-221 - - - - - 
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NM_004526 MCM2 - - - - - - - - Y 
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let-
7c/miR-
221 
miR-
221/let-
7c 
- 
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7c/miR-
221 
miR-221 23333386 Y - - 
NM_004333 BRAF - - - - - - Y - Y 
           
           
NM_020529 NFKBIA - - - - - - Y Y Y 
           
           
NM_002229 JUNB - - - let-7c - - - - - 
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NM_002908 REL - - - - - - Y - - 
NM_002880 RAF1 - - - - - - Y - - 
NM_012115 CASP8AP2 - - - miR-221 - - - - - 
NM_013254 TBK1 - - - - - - Y - - 
NM_003954 MAP3K14 - - - - - - - - - 
NM_004052 BNIP3 - - - - - - - - - 
NM_003106 SOX2 - - - - - - - - - 
NM_000346 SOX9 - - - - - - - Y - 
           
           
NM_006914 RORB - - 
miR-
221 
miR-221 - - - - Y 
           
           
NM_005634 SOX3 - - - - - - - - - 
NM_004189 SOX14 - - - - - - - - - 
NM_018419 SOX18 - - - - - - - - - 
NM_031439 SOX7 - - - - - - - - - 
NM_001363 DKC1 - - - - - - - - - 
NM_022454 SOX17 - - - - - - - - - 
 
